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Abstract: Arachidonic acid (ARA, 20:4n-6) is an n-6 polyunsaturated 20-carbon fatty acid formed by
the biosynthesis from linoleic acid (LA, 18:2n-6). This review considers the essential role that ARA
plays in infant development. ARA is always present in human milk at a relatively fixed level and is
accumulated in tissues throughout the body where it serves several important functions. Without the
provision of preformed ARA in human milk or infant formula the growing infant cannot maintain
ARA levels from synthetic pathways alone that are sufficient to meet metabolic demand. During
late infancy and early childhood the amount of dietary ARA provided by solid foods is low. ARA
serves as a precursor to leukotrienes, prostaglandins, and thromboxanes, collectively known as
eicosanoids which are important for immunity and immune response. There is strong evidence based
on animal and human studies that ARA is critical for infant growth, brain development, and health.
These studies also demonstrate the importance of balancing the amounts of ARA and DHA as too
much DHA may suppress the benefits provided by ARA. Both ARA and DHA have been added
to infant formulas and follow-on formulas for more than two decades. The amounts and ratios of
ARA and DHA needed in infant formula are discussed based on an in depth review of the available
scientific evidence.
Keywords: arachidonic acid; docosahexaenoic acid; infant formula; growth; human milk; long-chain
polyunsaturated fatty acids
1. Introduction
During the first year of life, infants have special nutritional requirements to maintain a healthy
body and support rapid growth and development. Human milk is typically the sole source of nutrition
that must supply the infant with appropriate amounts of energy and nutrients. The long-chain
polyunsaturated fatty acids (LCPUFA), docosahexaenoic acid (DHA, 22:6n-3) and arachidonic acid
(ARA, 20:4n-6) are always present in human milk. These fatty acids play key roles in the structure and
function of human tissues, immune function, and brain and retinal development during gestation and
infancy [1,2]. Although breastfeeding is considered the ideal way to nourish infants, recent nutrition
surveys report that the majority of infants in developed countries receive at least some infant formula
during the first year of life [3,4].
Both ARA and DHA have been added to infant formulas in the United States since 2001, although
supplementation began in Europe much earlier. Most infant formulas contain 0.2% to 0.4% of total
fatty acids as DHA and between 0.35% and 0.7% of total fatty acids as ARA based on worldwide
averages of DHA and ARA content in human milk [5] and the recommendations from a number of
international expert groups [6–9]. Thus, all commercially available infant formulas contain preformed
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ARA at levels equal to or higher than the DHA content in order to maintain adequate DHA and ARA
status in non-breastfed infants.
Both α-linolenic acid (ALA, 18:3n-3) and linoleic acid (LA, 18:2n-6) are regarded as nutritionally
essential fatty acids [10]. However, as Lauritzen et al. [10] point out, all classic signs of essential
fatty acid (EFA) deficiency can be completely reversed by the administration of n-6 fatty acids alone,
particularly ARA. With respect to infants, the presence of a relatively fixed level of preformed ARA in
human milk and the active accumulation of ARA by tissues throughout the body support the concept
of the essentiality of ARA. Previously, a description of the essentiality of ARA during infancy has not
been considered in detail, although a brief outline of the essentiality of n-6 and n-3 polyunsaturated
fatty acids was presented by Lauritzen et al. [10] in 2001.
The purpose of this paper is to review the essentiality of ARA for infant growth and development.
We consider both animal models and human studies of ARA. We describe: (1) ARA accumulation and
function in brain and tissues; (2) ARA content in human milk and in various tissues, including rates
of accretion during gestation and early infancy; (3) the structure and biosynthesis of ARA from LA
and its role as a precursor to leukotrienes, prostaglandins, and thromboxanes, collectively known as
eicosanoids; (4) dietary intakes of ARA during late infancy and early childhood when non-breast milk
food items are introduced into the diet; (5) immune system development and the dual role of PGE2
and its receptors in modulating the inflammatory response during infancy; (6) bone metabolism and
growth; (7) regulation of cardiac function; (8) consequences of ARA deficiency; (9) the importance
of ARA for optimal brain and central nervous system development; (10) the history, reasons for, and
nutritional effects of adding both DHA and ARA to infant formulas, with an emphasis on the effects
of ARA; (11) the importance of ARA in infant health; and (12) the regulatory requirements for ARA
and DHA in infant formulas. Based on a detailed review of the scientific literature presented herein,
recommendations for dietary intakes ARA during infancy are provided.
2. ARA Accumulation and Function in Brain and Tissue
Over the last decade, there has been increased understanding of the molecular roles that the n-3
and n-6 PUFA play in brain and cellular function. The variety of functions shown to be related to ARA
indicates its importance and essentiality in the metabolic chain of events leading to brain structural
lipid development, signaling, and many basic cellular functions.
ARA is indispensable for brain growth where it plays an important role in cell division and
signaling [11]. The brain in mammals consists of 60% fat, which requires DHA and ARA for its growth
and function [12]. Across different species of mammals there is little variation in DHA and ARA
composition of the brain. ARA is one of the most abundant fatty acids in the brain, and compared
with DHA, ARA is present in similar quantities [13,14]. The two fatty acids account for approximately
~25% of its total fatty acid content predominately in the form of phospholipids and thus are major
structural components of neural cellular membranes.
ARA rapidly accumulates in the brain during development [1,14,15] which takes place from the
beginning of the third trimester of gestation up to about 2 years of age [16] (Figure 1). As shown in
brain kinetics in fetal baboons, [17] in addition to maternal preformed ARA, LA may be transported
across the blood-brain barrier despite its very low content within brain lipids. The brain has an active
desaturation/elongation system that converts LA to ARA [17]. ARA activity is higher in brain than in
other organs such as the liver. However, the conversion of LA to ARA is low (see below).
The maximum rate of brain growth is primarily associated with myelination [14]. In animal
models, approximately 50% of the adult amounts of ARA and DHA accumulate in rat brain during the
period before myelination and at 15 days after birth when myelination has just started [14]. Diets low in
LCPUFA adversely affect the development of the myelin lipids needed early in brain development [14].
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Figure 1. Long‐chain polyunsaturated  fatty acids  (LCPUFA) accretion  in  the human brain during 
perinatal development (Data from Martinez [15]). 
ARA  has  several  functions  in  the  brain. ARA mediates  neuronal  firing  [18],  signaling  [19],   
and  long‐term  potentiation  [20].  ARA  also  helps  maintain  membrane  order  and  hippocampal 
plasticity  [21],  defends  the  brain  against  oxidative  stress  in  the  hippocampus  by  activating  the 
peroxisome  proliferator‐activated  receptor  gamma  (PPARγ),  and  aids  in  the  synthesis  of  new 
protein in tissue [22]. 
A  potentially  important  aspect  of ARA metabolism  in  vivo  is  its  function  as  an  immediate 
precursor for adrenic acid (22:4n‐6) [23]. Adrenic acid is the third most abundant PUFA in the brain 
that is found in large quantities in myelin lipids, particularly in phosphatidylethanolamine (PE) [1]. 
Rapid accumulation of adrenic acid, like ARA, occurs during the early post‐natal period of the brain 
growth  spurt  in  infants.  The  conversion  of  ARA  to  adrenic  acid  may  represent  an  important 
pathway for ARA utilization in infants in order to meet the rapid increase of adrenic acid needed for 
neural tissue development. 
Using a single dose of U‐13C‐labeled ARA to investigate preformed ARA utilization in baboon 
neonates, Wijendran  et al.  [23]  reported  that  a major portion  of ARA  consumed  (79%–93%) was 
accumulated as ARA in tissue lipids, consistent with its primary function as a principal constituent 
of membrane  lipids. Approximately 5%  to 16% of ARA was converted  to adrenic acid. Based on 
tracer data, net accretion of ARA and adrenic acid during  the  first 4 weeks of age  in  the neonate 
baboon brain was 17% and 8%, respectively, corresponding to efficiencies (i.e., percentage of dose 
recovered in brain) of 0.48% and 0.54% of dietary levels, respectively. 
To  determine  the  effects  that  differing  DHA  to  ARA  ratios  have  on  tissue  fatty  acids, 
twelve‐week‐old  full  term  baboons were  randomized  to  one  of  three diets:  control  (no DHA  or 
ARA), moderate (0.33% DHA, 0.67% ARA) and high LCPUFA (1.00% DHA, 0.67% ARA) [24]. In all 
groups, DHA levels increased significantly in liver, heart, plasma and in the central nervous system 
(CNS) regions (precentral gyrus, frontal cortex, inferior and superior colliculi, globus pallidus, and 
caudate). The formula with the highest level of DHA significantly reduced ARA levels in two areas 
of the brain (superior colliculus and globus pallidus), indicating its competition with ARA and the 
importance of a proper balance of DHA to ARA. 
Phosphatidylcholine  (PC)  is  a  lipid  class  that  is  a  major  component  of  most  intracellular 
membranes [25]. Some intracellular lipid bilayers include PC containing ARA (ARA‐PC). ARA‐PC 
functions as a retrograde messenger in long‐term potentiation of synapses in the hippocampus CA1 
region [26] and is involved in migration of neurons in the cerebral cortex [27]. 
Using  imaging mass  spectrometry, Yang et al.  [25] characterized  the distribution of ARA‐PC 
within  cultured  neurons  of  the  superior  cervical  ganglia  and  found  an  increasing  gradient  of 
ARA‐PC along the proximodistal axonal axis that may provide a source for free ARA release [25]. 
Released free ARA is known to activate protein kinases and ion channels, inhibit neurotransmitter 
uptake,  and  enhance  synaptic  transmission  [11].  Free  ARA  therefore  modulates  neuronal 
excitability.  As  ARA  mediates  intracellular  signaling  the  concentration  of  free  ARA  must  be 
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ARA has several functions in the brain. ARA mediates neuronal firing [18], signaling [19],
and long-term potentiation [20]. ARA also helps maintain membrane order and hippocampal
plasticity [21], defends the brain against oxidative stress in the hippocampus by activating the
peroxisome proliferator-activated receptor gamma (PPARγ), and aids in the synthesis of new protein
in tissue [22].
A potentially important aspect of ARA metabolism in vivo is its function as an immediate precursor
for adrenic acid (22:4n-6) [23]. Adrenic acid is the third most abundant PUFA in the brain that is
found in large quantities in myelin lipids, particularly in phosphatidylethanolamine (PE) [1]. Rapid
accumulation of adrenic acid, like ARA, occurs during the early post-natal period of the brain growth
spurt in infants. The conversion of ARA to adrenic acid may represent an important pathway for
ARA utilization in infants in order to meet the rapid increase of adrenic acid needed for neural
tissue development.
Using a single dose of U-13C-labeled ARA to investigate preformed ARA utilization in baboon
neonates, Wijendran et al. [23] reported that a major portion of ARA consumed (79%–93%) was
accumulated as ARA in tissue lipids, consistent with its primary function as a principal constituent of
membrane lipids. Approximately 5% to 16% of ARA was converted to adrenic acid. Based on tracer
data, net accretion of ARA and adrenic acid during the first 4 weeks of age in the neonate baboon brain
was 17% and 8%, respectively, corresponding to efficiencies (i.e., percentage of dose recovered in brain)
of 0.48% and 0.54% of dietary levels, respectively.
To determine the effects that differing DHA to ARA ratios have on tissue fatty acids,
twelve-week-old full term baboons were randomized to one of three diets: control (no DHA or
ARA), moderate (0.33% DHA, 0.67% ARA) and high LCPUFA (1.00% DHA, 0.67% ARA) [24]. In all
groups, DHA levels increased significantly in liver, heart, plasma and in the central nervous system
(CNS) regions (precentral gyrus, frontal cortex, inferior and superior colliculi, globus pallidus, and
caudate). The formula with the highest level of DHA significantly reduced ARA levels in two areas
of the brain (superior colliculus and globus pallidus), indicating its competition with ARA and the
importance of a proper balance of DHA to ARA.
Phosphatidylcholine (PC) is a lipid class that is a major component of most intracellular
membranes [25]. Some intracellular lipid bilayers include PC containing ARA (ARA-PC). ARA-PC
functions as a retrograde messenger in long-term potentiation of synapses in the hippocampus CA1
region [26] and is involved in migration of neurons in the cerebral cortex [27].
Using imaging mass spectrometry, Yang et al. [25] characterized the distribution of ARA-PC
within cultured neurons of the superior cervical ganglia and found an increasing gradient of ARA-PC
along the proximodistal axonal axis that may provide a source for free ARA release [25]. Released
free ARA is known to activate protein kinases and ion channels, inhibit neurotransmitter uptake, and
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enhance synaptic transmission [11]. Free ARA therefore modulates neuronal excitability. As ARA
mediates intracellular signaling the concentration of free ARA must be maintained at precise levels
within the cells. A higher concentration of ARA-PC near the axon terminal might provide a timely
source of ARA when needed during the activated period [25].
ARA also is responsible for the activation of syntaxin-3 (STX-3), a plasma membrane protein
involved in the growth and repair of neurites [28]. Growth of neurite processes from the cell body is
a critical step in neuronal development. STX-3 serves as a single effector molecule and direct target for
ARA [28]. Neurite growth closely correlates with the ability of ARA to activate STX-3 in membrane
expansion at growth cones [28].
ARA also enhances the engagement of STX-3 with the fusogenic soluble N-ethylmaleimide-
sensitive factor attachment protein receptors (SNARE complex), proteins that form a ternary complex
that drives exocytosis [29]. In the brain, at the neuromuscular junction, and in endocrine organs, a set
of three SNARE proteins has a primary role in producing fusion of vesicular and plasma membranes.
The formation of this SNARE complex drives membrane fusion which leads to the release of vesicular
cargo into the extracellular spaces [29]. Darios and colleagues [29] report that α-synuclein, a synaptic
modulatory protein implicated in the development of Parkinson disease, can sequester ARA and
thereby block the activation of the SNARE complex. This finding underlines the importance of ARA
for the regulation of synaptic transmission and transport.
Detergent resistant microdomains, also referred to as lipid rafts, are specialized regions within
plasma membranes [30]. These microdomains serve as platforms for biomechanical interactions
between the lipid and protein components of signal transduction pathways [30–32]. The outer leaflet of
lipid rafts is highly enriched with glycol-sphingolipids and cholesterol [32]. The inner, or cytosol facing
leaflet is enriched with alkenyl forms of PE which have been termed plasmenylethanolamine. Electrospray
ionization/mass spectrometric analysis has shown that the ARA-containing plasmenylethanolamine
represents as much as 50% of the phospholipids of the cytosolic leaflet [31]. This is consistent with
a role of PE as an important source of ARA within the cell.
Stearoyl-2-arachidonoyl is a highly abundant species of phosphatidylinositol (PI) found in the
phosphorylated forms of PI, the phosphoinositides [33–38]. In addition to serving as a substrate
for phospholipase C to produce inositol-triphosphate and diacylglycerol, phosphoinositides serve
important biochemical functions including lipid signaling, cell signaling and membrane trafficking.
Phosphoinositides perform these roles in part by serving as adaptors for protein-protein and
protein-membrane interactions in order to facilitate and/or regulate G-receptor protein activity and
signal transduction, and trafficking of various metabolites such as cholesterol or calcium, or other
ions, between cellular compartments [39–43]. These biochemical functions of ARA demonstrate its
importance for cell signaling, trafficking and regulation of spatial-temporal interactions between
cellular structures.
3. Levels of ARA in Human Milk, Brain, and Tissues
Fat is a critical component of human milk that provides energy and nutrients needed for the
development of the CNS [10]. DHA and ARA are the principal LCPUFA found in human milk.
The synthesis of DHA and ARA is limited in infants [5] and both DHA and ARA must be obtained
from dietary sources. Amounts of DHA and ARA in human milk tend to vary by diet, nutritional
status, and other factors [5]. Based on data from 65 studies of human milk from 2474 women, the
mean concentration of ARA (by weight) was 0.47% ˘ 0.13% (range 0.24% to 1.0%) whereas the mean
concentration of DHA was 0.32% ˘ 0.22% (range 0.06% to 1.4%) [5]. The DHA concentration in human
milk is lower and more variable than ARA. The level of ARA in human milk is much more stable.
The relatively stable content of ARA in human milk is biologically important because it provides
preformed ARA consistently at a time when brain growth and development is most critical. The
majority of ARA in human milk does not derive from dietary LA but rather from maternal stores
of ARA [44]. The correlation between DHA and ARA is low, which may reflect a higher degree of
variability in the ratio of DHA to ARA in individual human milk samples [5].
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The composition of the brain is dominated by ARA and DHA [45]. During pregnancy, both ARA
and DHA are preferentially transferred across the placenta [46] and sequestered in the developing
brain from the earliest phases of its growth. After birth, human milk provides both DHA and ARA to
the breastfed infant [47] with a rapid rise towards adult levels of DHA and ARA in the brain within the
first two years of life [48]. ARA is found at a level comparable to that of DHA in neural membranes,
particularly those of the brain [49].
Based on estimated total body content of ARA from fetal organ weights during the last trimester
of pregnancy and early infancy the relative amount of brain ARA decreases, but because of brain
growth the absolute amount of ARA increases [50]. In fact, the absolute amount of ARA increases in
all organs with increasing gestational age while the relative contribution (g per 100 g fatty acids; g %)
decreases [50]. At 25 weeks gestation, the whole fetal body contains about 1.1 g ARA which increases
to 4.2 g ARA at 35 weeks gestation. A full-term infant (3500 g) has about 7.6 g of ARA. The accretion
rate of ARA is estimated to be 6.1 mg/day during the first 25 weeks and increases to 95.2 mg/day by
35–40 weeks gestation. The fetal accretion rate for ARA is 2-fold that of DHA [50]. Most of the bodily
ARA at 25 and 40 weeks is located in skeletal muscle, adipose tissue and the brain, in that order [50].
In human infant central nervous tissue (cerebral cortex and retina) ARA comprises approximately
10%–12% of total fatty acids [49]. The amount of ARA in central nervous tissue appears to be influenced
to a greater extent by postnatal age than by dietary ARA supply [49]. Samples of frontal cerebral
cortex obtained from 58 human autopsies (mean age 40 ˘ 29 years) indicated that the relative levels of
PUFA expressed as a percentage of total fatty acids generally decrease with age with the exception of
DHA [51].
The distribution of n-6 and n-3 PUFA was determined in various viscera and tissues within the
whole body of rats fed a diet containing 10 wt % fat (15% linoleate and 3% α-linolenate) until 7 weeks
of age when they were sacrificed [52] (Figure 2).
The rat whole body was comprised of primarily saturated fatty acids (48.4% of total fatty acids)
while the monounsaturated fatty acids were present in the second greatest amount (34.8%). The total
amount of n-6 PUFA was 12.0% and was more than 5-fold greater than the total n-3 PUFA. The n-6
PUFA with the highest content was LA (10.1%) followed by ARA (1.4%). ARA was the major PUFA
in nearly every tissue and was the major PUFA in most internal organs. The tissues with the highest
content of ARA were plasma (25.3%) followed by kidney, red blood cells (RBC), and spleen, ranging
from 18.7% to 23.5%. Brown adipose, white adipose and the eye contained very low amounts of ARA
(<1.0%). For each compartment in the rat body, the total ARA/organ was highest for muscle, then
liver, adipose, and carcass. In terms of fatty acid composition expressed as a percentage, ARA was
highest in the circulation, kidney, and the spleen.
As shown in rat pups, when tissues are deprived of n-3 PUFA, the accretion of ARA from
LA is increased and ARA is further metabolized to produce docosapentaenoic acid (22:5n-6, DPA)
which accumulates in tissues [53], particularly in the nervous system. The accumulated DPA in turn
reciprocally replaces lost DHA in tissue [53].
Pigs fed varying amounts of ARA and DHA levels after birth and then sacrificed at day 28 showed
that dietary ARA had little effect on tissue DHA accretion [54], but heart tissue was particularly
sensitive to ARA intake. These observations are particularly notable because the pigs were fed ARA at
a level of 0.53% of total fatty acids. This level is slightly above the worldwide ARA mean in human
milk and 0.67% of total fatty acids is the level currently added to many infant formulas and is near the
high end of human milk ARA levels [5]. Neonatal pigs serve as a practical biomedical model of human
infant development due to their similar metabolic responses, genetics of the fatty acid desaturases,
and rates of perinatal brain growth [5]. The importance of ARA for the heart is discussed in greater
detail in Section 8.
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Figure  2.  Distribution  of  fatty  acids  in  25  different  tissue  compartments  in  young  male  rats. 
Abbreviations:  ATL,  adrenal  gland,  thyroid  gland,  mandibular  gland,  and  lymph  nodes;  RBC,   
red blood  cell; SG,  salivary gland; ADB, brown adipose  tissue; ADW, white adipose  tissue  (from   
Salem et al. [52]). 
4. ARA Biosynthesis and Metabolism 
ARA  is  an  n‐6  polyunsaturated  20‐carbon  essential  fatty  acid  formed  by  biosynthesis  from   
LA [10]. ARA is a precursor to leukotrienes, prostaglandins, and thromboxanes, collectively known 
as  eicosanoids  [55,56]. ARA  is  found  in membrane  phospholipids  throughout  the  body  and  is 
particularly abundant in the brain, muscles and liver. The metabolic pathways of the n‐6 series and 
n‐3 series are shown in Figure 3. 
Figure 2. Distribution of fatty acids in 25 different tissue compartments in young male rats.
Abbreviations: ATL, adrenal gland, thyroid gland, mandibular gland, and lymph nodes; RBC, red blood
cell; SG, salivary gland; ADB, brown adipose tissue; ADW, white adipose tissue (from Salem et al. [52]).
4. ARA Biosynthesis and Metabolism
ARA is an n-6 polyunsaturated 20-carbon essential fatty acid formed by biosynthesis from
LA [10]. ARA is a precursor to leukotrienes, prostaglandins, and thromboxanes, collectively known as
eicosanoids [55,56]. ARA is found in membrane phospholipids throughout the body and is particularly
abundant in the brain, muscles and liver. The etabolic pathways of the n-6 series and n-3 series are
shown in Figure 3.
Nutrients 2016, 8, 216 7 of 47Nutrients 2016, 8, 216  7 of 46 
 
 
Figure 3. Metabolic pathways of linoleic and α‐linolenic acid (Adapted from Lauritzen et al. [10]). 
The use of stable isotope labelled fatty acids to investigate essential fatty acid metabolism was 
pioneered in the 1930s with the first identifiable study done by Schoenheimer and Rittenberg [57]. 
Several decades later, Nichaman et al. [58] gave four adult subjects 14C‐labeled LA and found a very 
small  but  significant  incorporation  into  plasma  phospholipid ARA  acid  based  on  responses  in 
gas‐radiochromatography.  Similarly,  14C‐labeled  LA was  shown  to  be  converted  to  14C‐ARA  in 
human  fetal  liver  microsomes,  in  vitro  [59].  El  Boustani  et  al.  [60]  studied  the  conversion  of 
deuterated dihommo‐gamma linoleic acid (20:3n‐6, DGLA) into ARA in plasma phospholipid and 
triglyceride fractions in vivo in diabetic patients. After a 2 g isotope ingestion, a maximum of 5 mg of 
labelled ARA/L was observed in plasma. The authors stated that “this was consistent with the very 
low ∆5 desaturase activity observed in vitro in the human liver”.   
In the 1980s, Emken and colleagues [61] developed stable isotope technology in adult humans. 
In an early study of deuterated‐LA metabolism in vivo, when a large dose of over 14 g of isotope was 
given, the authors concluded that “interconversion products such as deuterium‐labeled …20:3 and 
20:4 were not detected in any of the lipid classes” [62]. They calculated that a conversion of as little as 
0.00012% would have been detectable. The absence of any LA metabolism to ARA was confirmed in 
a subsequent study even where labelled‐ALA was clearly incorporated into EPA and DHA [61]. 
In 1995, Demmelmair et al. [63] used natural abundance 13C measurements in corn oil fed infants 
to  demonstrate  LA  conversion  to  ARA.  They  observed  conversion  but  concluded  that   
“the activity of the enzyme system seems to be limited”. Shortly afterwards, the conversion of LA to 
ARA  was  conclusively  and  directly  demonstrated  in  newborn  infants  using  stable  isotope 
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The use of stable isotope labelled fatty acids to investigate essential fatty acid metabolism was
pioneered in the 1930s with the first identifiable study done by Schoenheimer and Rittenberg [57].
Several decades later, Nichaman et al. [58] gave four adult subjects 14C-labeled LA and found a very
small but significant incorporation into plasma phospholipid ARA acid based on responses in
gas-radiochromatography. Similarly, 14C-labeled LA was shown to be converted to 14C-ARA in
human fetal liver microsomes, in vitro [59]. El Boustani et al. [60] studied the conversion of deuterated
dihommo-gamma linoleic acid (20:3n-6, DGLA) into ARA in plasma phospholipid and triglyceride
fractions in vivo in diabetic patients. After a 2 g isotope ingestion, a maximum of 5 mg of labelled
ARA/L was observed in plasma. The authors stated that “this was consistent with the very low ∆5
desaturase activity observed in vitro in the human liver”.
In the 1980s, Emken and colleagues [61] developed stable isotope technology in adult humans.
In an early study of deuterated-LA metabolism in vivo, when a large dose of over 14 g of isotope was
given, the authors concluded that “interconversion products such as deuterium-labeled . . . 20:3 and
20:4 were not detected in any of the lipid classes” [62]. They calculated that a conversion of as little as
0.00012% would have been detectable. The absence of any LA metabolism to ARA was confirmed in
a subsequent study even where labelled-ALA was clearly incorporated into EPA and DHA [61].
In 1995, Demmelmair et al. [63] used natural abundance 13C measurements in corn oil fed infants to
demonstrate LA conversion to ARA. They observed conversion but concluded that “the activity of the
enzyme system seems to be limited”. Shortly afterwards, the conversion of LA to ARA was conclusively
and directly demonstrated in newborn infants using stable isotope technology by Salem et al. [64]. The
D5-LA was used together with a highly sensitive NCI GC/MS method after PFB derivatization [65].
With this new methodology, the deuterated fatty acid could be chromatographically separated from
its corresponding endogenous analogue and so the signal of the stable isotope labeled metabolite
would not be obscured by the much larger signal from the endogenous fatty acid. A crude estimate
was made of the net accretion of ARA over the six day period of the study which was 53 mg, or
about 9 mg ARA/day. Such estimates of “net synthesis” treated the organism as if the synthesis
was occurring within the bloodstream and this is clearly not the case. In addition, what was being
measured is the synthesis, minus the catabolism, plus the transport/release into a compartment such
as the bloodstream where it can be sampled. Carnielli et al. [66] used a similar methodology to confirm
the conversion of LA to ARA in very low birth-weight infants using 13C-labeled LA.
Pawlosky et al. [67] studied stable isotope labeled LA and DGLA metabolism to ARA in
10 newborn human infants within the first week of life in vivo and performed compartmental modeling
to provide an estimate of the synthetic rates. Formula and breast milk intakes were considered so that
ARA and other PUFA intake could be estimated; LA and ARA intake was estimated at 3 g/kg/day and
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2.8 mg/kg/day, respectively. They concluded that “the mean daily rate of synthesis and turnover of
20:4n-6 in plasma of infants were estimated to be from 0.06 to 2.1 mg/day . . . and from 0 to 51 mg/day
(mean 10.2)” [67]. They went on to say that “such rates of synthesis are incapable of sustaining plasma
20:4n-6 concentrations in nearly all of these subjects necessitating an intake of ~4 mg/kg/day from
either human milk or a supplement”. The fractional rate of conversion (FRC) observed in this study
was 2.7% which is even more than that observed by Sauerwald et al. [68] who calculated an FSR of
0.4% to 1.1% depending upon the ALA content of the formula.
Carnielli and colleagues in 2007 [69] studied LA conversion to ARA using natural abundance 13C
measurements in preterm infants in vivo in those fed LCPUFA or no LCPUFA-containing formulas
at 1, 3 and 7 months of age. These authors show that ARA synthesis is decreasing with age as it fell
from 26.7 mg/kg/day to 14.4 mg/kg/day and then to 11.6 mg/kg/day from 1 to 3 to 7 months of age,
respectively. It seems that the endogenous synthesis rate in these infants was inadequate as the ARA
plasma phospholipid level fell from 5.6 mol% in the ARA fed group to 1.9 mol% in the no ARA group,
a 66% drop. This underlines the inadequacy of LA alone as a source of ARA and the requirement
for preformed ARA in the infant diet if blood levels of ARA are to be maintained similar to those in
breastfed infants.
5. Global Intake of ARA in Early Life
In contrast to n-3 LCPUFA, there are few data relating to dietary intakes of n-6 LCPUFA in early
life. In relation to dietary ARA, many regulatory agencies have tended to assume that beyond the
age of 6 months, the endogenous synthesis of ARA will meet the needs of infants and young children
during this period of rapid growth and development [70,71]. However, studies have shown that the
endogenous synthesis of both DHA and ARA may be insufficient with evidence of blood and tissue
concentrations decreasing after birth if there is not an exogenous supply [49,72].
The World Health Organization (WHO) [73,74] and the American Academy of Pediatrics [75]
recommend that infants should be exclusively breastfed for the first six months of life to achieve optimal
growth, development and health. Thereafter, to meet their dietary requirements during growth,
infants should receive nutritionally adequate and safe complementary foods while breastfeeding
continues for up to two years of age or beyond [73,74]. However, there is widespread variation in
compliance with this recommendation in both developed and developing countries. In an evaluation
of 33 developing countries, where the health benefits of this policy could have the greatest impact,
exclusive breastfeeding occurred in 46% of countries, the median duration of breastfeeding was
18.6 months and over 30% received complementary foods before 6 months of age [76]. The extent
to which variation in feeding practices may influence global intakes of ARA and infant growth and
development in early life needs to be further evaluated.
5.1. ARA Intake from Human Milk
In exclusively breastfed infants, the mean human milk intake at 6 months has been measured to be
854 g/day [73,74]. Based on those data and an estimation that 4.2% of human milk is composed of fatty
acids [77] the average ARA and DHA intakes in exclusively breastfed infants at 6 months of age are
about 169 mg/day and 115 mg/day, respectively. Moreover, many infants continue to receive human
milk throughout the first year of life and longer. It is estimated that at 12 months of age the intake of
human milk is in the range of 600–900 g/day [73,74]. This amount provides infants with an ARA intake
from human milk in the range of 118–178 mg/day. The mean estimated ARA intake is approximately
12–18 mg/kg/day when adjusted for body weight using weight-for-age percentiles [78].
5.2. ARA Intake from Infant Formula
Infant formulas typically contain levels of ARA and DHA at 140 mg/day and 100 mg/day,
respectfully, based on worldwide averages of ARA and DHA content in human milk [5]. Therefore,
intakes of ARA and DHA from infant formula are similar to those provided from human milk.
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5.3. ARA Intake from Weaning Foods
In both developed and developing countries weaning foods contain low amounts of fat, which
results in a sharp transition from adequate fat intake during breastfeeding to significantly lower fat
intake when children are weaned from the breast [79,80]. The main food sources of ARA are beef,
poultry, eggs and seafood. Complementary foods in low-income countries are typically cereal-based
and therefore LCPUFA dietary intake from these weaning foods may be minimal [79]. Countries with
the lowest gross national product (GNP) (e.g., Malawi, Ethiopia, Bangladesh, Burkina Faso, Ghana
and India) had a mean percentage of total PUFA from animal source foods of 4.9% vs. countries with
a higher GNP (Vietnam, Bolivia, Indonesia, Guatemala, China, South Africa, Mexico) where the mean
percentage of total PUFA from animal food sources was 18.1% [79].
Intakes of ARA (mean mg/day and estimated mean mg/kg/day) from several developing and
developed countries are presented in Table 1. In the village of Keneba, Gambia, estimated mean intake
of ARA during the period of 0–6 months when infants are predominantly breastfed was 90 mg/day and
as complementary foods were introduced the ARA intake fell steadily to 10 mg/day at 24 months [81].
In Heqing County, Yunnan Province China, the mean intake of ARA was 55 mg/day at 1 to 3 years of
age and 50 mg/day at 4 to 5 years of age [82].
Vulnerable infants and young children need energy- and nutrient-dense foods to grow and
develop both physically and mentally [83]. For these reasons, dietary diversity is now included
as a specific recommendation in the guidance for complementary feeding of the breastfed child
aged 6 to 23 months [83]. Many factors contribute to limited dietary diversity including economic
limitations, religious beliefs, and a concern that infants under 1 year of age cannot digest animal
sourced foods [84,85]. There is also a widely held perception by parents that fish may be associated
with allergic reactions [85,86].
Even in developed countries where dietary diversity is higher and meat and eggs contribute
more to the complementary diet, the detrimental impact of the introduction of complementary feeding
with low amounts of ARA and DHA content is evident. For example, mean ARA intake in German
infants/toddlers decreased from 72 mg/day at 6 months of age to 24 mg/day at 9 months of age [87]
(Table 1). In a separate study, these authors reported that predominately breastfed German infants had
an ARA intake of 103 mg/day at 3 months of age and this amount declined to 24 mg/day at 9 months
when human milk represented only 20% of the diet [88].
One hundred-seventy-four Italian breastfed children were followed from birth to 12 months
of age [89]. Human milk samples were analyzed. The mean ARA intake from human milk was
95.6 mg/day at 1 month, 109.6 mg/day at 2 months, and 101.1 mg/day at 3 months. However, at
6 months of age, ARA intake sharply declined to 58.7 mg/day.
In Belgium, mean intakes of ARA were very low at 2.5 to 3 years of age and at 4 to 6.5 years of age
(17 and 18 mg/day, respectively) [90] (Table 1). In Australia, national intake data indicated that 2 to
3 year-old and 4 to 7 year-old children consumed 16 mg/day and 22 mg/day of ARA, respectively [91].
Much higher mean ARA intakes were reported for Canadian children living in Vancouver where
intakes ranged from 133 to 260 mg/day among children 1.5 to 5 years of age [92]. However, in children
aged 4 to 7 years of age from Ontario, Canada, mean intake of ARA was lower (57 mg/day) [93].
Based on food records from the National Health and Nutrition Examination Survey (NHANES
2003–2008), the mean intake of ARA in American children at 1 to 4 years of age was 60 mg/day [94].
Most of the ARA was obtained from poultry (32.5%), eggs (27.5%), and meat dishes (20.9%). The latest
NHANES data from 2015 indicate that the mean ARA intake of American children at 2 to 5 years of
age increased to 80 mg/day [95].
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Table 1. ARA intakes in developed and developing countries during the first 2 years of life.
Country Age Method Mean ARA Intake(mg/Day) (mg/kg/Day) 1
Australia [91]
2–3 years 1-day weighed food record 16 (1.3)
1-day weighed food record 22 (1.8)
Belgium [90] 2–5 years 3 days food record 17 (1.4)
4–6.5 years 3 days food record 18 (1.0)
Canada [92,93]
1.5–2 years 1 day food frequency 133 (11.0)
2.1–3 years I day food frequency 260 (22.0)
3.1–5 years 1 day food frequency 226 (15.0)
4–7 years 3-days food records 57 (2.9)
China [82]
1–3 years 3 days 24 h recall 55 (4.6)
4–5 years 3 days 24 h recall 50 (2.5)
Gambia [82]
0–6 months 1 day weighed food monthly 90 (15.0)
7–12 months 1 day weighed food monthly 70 (7.8)
13–17 months 1 day weighed food monthly 60 (6.7)
24 months 1 day weighed food monthly 10 (0.8)
Germany [87,88] 6 months 3 days weighed food record 72 (12.0)
9 months 3 days weighed food record 24 (2.7)
Italy [89]
1 month Human milk composition 95.6 (29.0)
2 months Human milk composition 109.6 (33.0)
3 months Human milk composition 101.1 (16.9)
6 months Human milk composition 58.7 (9.8)
U.S. 2003–2008 [94] 1–4 years 1 day weighed food record 60 (5.0)
U.S. 2015 [95] 2–5 years 1 day weighed food record 80 (6.7)
Notes: 1 Estimated mean intake for ARA (9 mg/kg/day) for ages 0 month to 3 years was calculated using
median weight-for-age percentiles for boys, birth to 36 months, and from median body mass index for ages 4
through 19 years; from the Centers for Disease Control and Prevention-Growth Charts (CDC, [78]).
Based on these dietary intakes from local and national surveys, it is clear that the diets of young
children contain low levels of ARA. Reported mean intakes of ARA at 10 to 18 mg/day in developing
and developed countries are only about 10% of the amount of ARA available to infants fed human
milk or infant formulas containing DHA and ARA.
Birch et al. [96] reported that despite the introduction of a variety of solid foods at 17 weeks of
age, infants who did not receive an infant formula supplemented with ARA and DHA throughout
the first year of life had significantly lower levels of both of these fatty acids in plasma. The clinical
consequences of low intake of ARA have not been adequately investigated.
6. ARA and Its Role in Immune System Development and Function
There is growing evidence from preclinical and clinical studies that ARA plays an important
role in maintaining infant health through its effects on the immune system and through the
modulation of the inflammatory response [97]. The eicosanoids that ARA produces serve as both
mediators and regulators of inflammation [98] (Table 2). These immunomodulatory effects have
generated much interest in the potential roles that LCPUFA in general and ARA in particular have in
common inflammatory conditions in childhood such as asthma, eczema, atopic dermatitis, and food
allergies [97].
In cell membranes, ARA contributes to membrane order, has roles in signal transduction, and gene
expression, and provides substrate for production of important chemical mediators [99]. Although
ARA has been widely viewed as a pro-inflammatory agent, the eicosanoids that ARA produces serve
as both mediators and regulators of inflammation [98]. ARA-derived eicosanoids, and other oxidized
derivatives [98] are generated by the metabolic processes as shown in Figure 4.
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Table 2. Pro- and anti-inflammatory effects of prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) 1.
Eicosanoid Effects
PGE2
Proinflammatory
Induces fever
Increases vascular permeability
Increases vasodilatation
Causes pain
Enhances pain caused by other agents
Anti-inflammatory
Inhibits production of TNF and IL-1
Inhibits 5-LOX (decreases 4-series LT production
Induces 15-LOX (increases lipoxin production)
LTB4
Proinflammatory
Increases vascular permeability
Enhances local blood flow
Chemotactic agent for leukocytes
Induces release of lysomal enzymes
Induces release of oxygen species by granulocytes
Increases production of TNF, IL-8, and IL-6
Notes: 1 IL, interleukin; LOX, lipoxygenase; TNF, tumor necrosis factor. From Calder [98].
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Figure 4. Generalized pathway for the conversion of ARA to eicosanoids. COX, cyclooxygenase;
HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; LOX, lipoxygenase;
LT, leukotriene; PG, prostaglandin; TX, thromboxane (from Calder [98]).
Another example of the dual role of PGE2 and its receptors in modulating the inflammatory
response has been described by Riccioti and FitzGerald [100]. During neuro-inflammation,
the LPS-induced PGE2 synthesis causes adverse effects in neurons resulting in lesions and
enhanced pain [101]. However, PGE2 also mediates bradykinin-induced neuroprotection by
blocking LPS and ATP-induced cytokine synthesis in microglia and in neuron-glia co-cultures [102].
The anti-inflammatory and neuro-protective effects of PGE2 are mediated by microglial EP2- and
EP4-receptors [100].
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ARA is the substrate for the biosynthesis of prostaglandins. Prostaglandins and thromboxane
A2 are collectively called prostanoids. Prostanoids are formed when ARA is released from the
plasma membrane by phospholipase and metabolized by the sequential actions of prostaglandin G/H
synthase, or cyclooxygenase (COX), and by respective synthesis [100]. Prostanoids serve a variety of
functions. The adhesion-type prostaglandins as well as prostacyclin are important in vasodilation and
in anti-thrombus formation [103]. The E series prostaglandins act to dilate arterioles and capillaries
to bring about a drop in blood pressure, relax vascular smooth muscle, open the bronchi of the
lungs, and enhance blood flow through the kidney [104]. Prostaglandins are also involved in sleep
regulation [105], febrile response [106], and in pain perception [107].
As discussed by Calder [98], the overall physiologic (or pathophysiologic) outcome associated
with the production of eicosanoids depends on the cells present, the nature of the stimulus, the
timing of eicosanoid production, and the sensitivity of the target cells and tissues to the type of
eicosanoids that are produced [98,108]. For example, studies have shown that prostaglandin PGE2,
acting as a pro-inflammatory agent, induces cyclooxygenase 2 (COX-2) in fibroblast cells and by
doing so up-regulates its own production [109] which in turn stimulates the production of IL-6
by macrophages (see Astudillo et al. [108] for a review of ARA metabolism by inflammatory cells).
As an anti-inflammatory agent, PGE2 inhibits 5-lipoxygenase (5-LOX) thereby decreasing production
of the 4-series leukotrienes [110].These 4-series leukotrienes induce 15-LOX which in turn promotes
the formation of lipoxins that aid the resolution phase of inflammation [110]. Thus, the ARA-derived
PGE2 has both pro- and anti-inflammatory effects (Table 2).
Leukotrienes, eoxins, lipoxins, and hydroperoxyeicosatetranoic acids (HPETEs) are synthesized
from ARA by lipoxgenase enzymes and metabolized to LTA4 [108]. LTA4 is unstable and can
be rapidly converted into LTB4 or LTC4. These three leukotrienes constitute the slow-reacting
substances involved in anaphylaxis that act in allergic response [111]. They contract smooth muscle
and affect vascular permeability. Eoxins are generally proinflammatory and are produced in the
same manner as leukotrienes, but by the action of 15-lipoxgenase [108]. Lipoxins are produced by
transcellular biosynthesis and have anti-inflammatory properties and are involved in the resolution of
inflammation [112].
In vitro and animal studies suggest that ARA has a critical role in immune cell growth in the
thymus, and in differentiation, migration, and proliferation of immune cells [98]. During early growth,
there is substantial accretion of ARA in the mouse thymus which corresponds to the enrichment of the
placental ARA for the fetus [98].
The immune system is composed of an integrated network of organs, tissues, cells and molecules
that work together to resist infection, but maintain tolerance to harmless factors such as “self”, antigens,
and allergens [113]. When a challenge is detected (e.g., an allergen or pathogen), cell signaling
between immune cells produces a coordinated immune response involving the release of cytokines
and eicosanoids, which under normal circumstances allows cells to communicate with each other to
neutralize and eliminate the challenge [114,115].
ARA is highly abundant in platelet membranes and is closely linked to many platelet
functions [116]. Due to their high numbers (i.e., normal platelet count of 1.50–4.00 ˆ 1011 platelets
per liter of blood [117] and their ability to release inflammatory mediators, platelets perform several
sentinel tasks and can quickly communicate with the cells of the immune system [118]. For example, in
inflammatory skin disorders, platelets recognize bacterial pathogens through interactions with Toll-like
receptors leading to the elimination of bacteria by release of antimicrobial peptides or by aggregation
of platelets around the bacteria [119]. An array of receptors present on platelet membranes facilitate
transduction of signals and coordinate release of chemokines, cytokines, and other inflammatory
mediators to regulate inflammation and respond to invading pathogens [118,119].
Inflammation is the immune’s systems response to infection and injury [98]. Inflammation
disorders are observed in infants, particularly those born prematurely [120]. Inflammation is
characterized by the production of inflammatory cytokines, inflammatory agents such as reactive
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oxygen species, adhesion molecules, and the ARA-derived eicosanoids, and other oxidized
derivatives [98]. N-3 LCPUFA decrease the production of the inflammatory mediators (eicosanoids,
cytokines, and reactive oxygen species) and expression of adhesion molecules [98] by replacing
ARA as an eicosanoid substrate and inhibiting ARA metabolism [98,121]. Aspirin and nonsteroidal
anti-inflammatory drugs (NSAIDs) also inhibit the cyclooxygenase-catalyzed conversion of ARA to
prostaglandins [122].
Although inflammation is perceived to be a serious health problem, the inflammation process is
in fact an intrinsically beneficial event. Offending factors are removed or destroyed and as a result
the affected tissues and physiological functions are restored. During the acute phase of inflammation,
there is a rapid influx of blood granulocytes, typically neutrophils, followed by monocytes that
mature into inflammatory macrophages [100]. The macrophages proliferate and affect the functions of
resident tissue macrophages. This initial acute phase causes the usual signs of inflammation: redness,
heat, swelling, and pain [100]. Once the initial adverse stimulus is removed via phagocytosis, the
inflammation reaction typically decreases and ultimately resolves. During the resolution phase of
inflammation, granulocytes are eliminated and macrophages and lymphocytes return to their normal
pre-inflammatory levels [100]. The usual outcome of the acute inflammatory process is successful
resolution and repair of tissue damage.
Eicosanoids and Their Effects on Hormones and Bone Formation
The typical definition of a hormone is a chemical substance produced in the body that controls
and regulates the activity of certain cells or organs [123]. Many hormones are secreted by special
glands, such as thyroid hormone produced by the thyroid gland. Eicosanoids are recognized as
different from hormones because they are not synthesized or stored in select tissues or endocrine
organs. Eicosanoids are synthesized in almost all tissues and exert their biological effect near the site of
their synthesis rather at a distance such as other hormones [124]. Despite these differences, eicosanoids
are generally classified as hormones [125]. Eicosanoids directly affect other hormones including
glycoprotein hormones. The glycoprotein hormones include luteinizing hormone, somatostatin, and
glucagon. Somatostatin is an important growth hormone that controls and regulates growth and cell
division [126]. It is the main hormone that stimulates cell proliferation and growth, and this hormone
must be regulated so that growth is controlled [126]. Insulin and glucagon release are also affected by
the eicosanoid derivatives, epoxy-eicosatrienoic acids [124].
ARA also plays an important role in the hormonal regulation of normal bone formation and whole
body mineral metabolism during infant and childhood growth (Table 3). During skeletal development,
the eicosanoids relay cellular, organ, and systemic signals to balance the calcium and phosphate needs
for bone formation and other metabolic activities [127,128]. During long bone growth, when bone
tissue is created, [127–130] ARA mediates vitamin D3-regulated chondrocyte maturation [131] and
proliferation [127,132–134] for the mineralization of skeletal growth plates (Figure 5).
A product of ARA, prostaglandin PGE2 is a potent regulator of cartilage formation or
chondrogenesis and resorption [135–139]. At low levels, PGE2 stimulates bone formation by increasing
the production of insulin-like growth factor, a powerful growth stimulator for bone, cartilage, and
muscle [140]. At high levels, PGE2 has the opposite effect: bone formation is reduced and resorption is
increased [140].
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Table 3. Roles of ARA in bone formation, metabolism, and mineral balance.
Metabolic Effector Physiological Roles of ARA
ARA [149] Maintain normal balance between bone mineral accrualand bone resorption during infant development
ARA, growth hormones [150,151] Increase insulin-like growth factor gene expression andinduction of osteoblast-dependent bone formation
Vitamin D3 [128,133]
Mediate vitamin D3 coordination of chondrocyte
proliferation in the epiphyseal growth plates of long
bones. Parathyroid hormone secretion
Calcium and phosphorous [152] Regulation of parathyroid hormone secretion in responseto blood mineral concentrations
Parathyroid hormone [149,150] ARA mediated/activated pathway involved in theactivation and secretion of vitamin D3 by kidneys
Physical activity [153]
ARA mediates bone adaptation to changes in physical
stress through mechanisms which mediate resorption
and remodeling
In studies of piglets fed formulas with differing levels of ARA (0.30%, 0.45%, 0.60% or 0.75% of
fat) plus the same level of DHA (0.1% of fat), proportions of ARA in plasma, liver and adipose were
dose dependent but bone modeling was not [150]. Whole-body bone mineral content was elevated
in the piglets fed the highest levels of ARA (0.60% and 0.75%) and was best predicted by dietary
ARA [150,154]. In addition, the 0.60% and 0.75% ARA groups had bone mineral content values closest
to that of a reference group of suckled piglets [150,155].
Overall, dietary provision of ARA serves a number of important roles in skeletal metabolism. ARA
functions as an important modulator of vitamin D regulation of chondrocyte proliferation and growth
plate mineralization. ARA derived metabolites are important inducers of osteoclast [156,157] and
osteoblast differentiation [158,159], and in modulating resorption of bone [139,149] by increasing IGF-1
gene expression [104,151] and circulating levels of IGF-1 [150]. ARA also responds to changes in stress
and mechanical loading [153,160], and accelerates bone repair and healing [142,161]. Additionally, in
term infants, cord blood ARA levels correlate positively with bone mineral density [155]. Thus, ARA
represents an important nutrient for infant and childhood bone development and metabolism.
7. ARA in Skeletal and Cardiac Muscle
Several animal studies have shown that the concentration of ARA in the heart is highly
sensitive to levels and ratios of ARA and DHA of the diet [24,54,162–164]. The amount of ARA
in cardiac tissue muscle is at concentrations 2 to 3 times greater than observed in skeletal muscle [52].
Analysis of the phospholipid composition of skeletal muscle biopsies collected from 56 children
<2 years of age indicated that ARA represented 16.5% of the total percentage of LCPUFA in muscle
phospholipids [165].
Repetitive force loading and unloading during ATP-dependent contraction of actin filaments are
major mechanical functions of heart muscle, and to a lesser extent, skeletal muscle [166]. ARA is critical
for muscle contraction [166–168]. In skeletal muscle, excitation–contraction coupling is the process by
which muscles contract [166] when a muscle action potential in the muscle fiber causes the myofibrils
to contract [169]. Excitation–contraction coupling relies on a direct coupling between key proteins, the
sarcoplasmic reticulum calcium release channel (the release of Ca2+ ions), and the voltage-gated L-type
calcium channels [170]. The release of Ca2+ ions from the sarcoplasmic reticulum causes binding
between actin and myosin to induce muscle contraction. This cycle is reset as calcium declines back
to resting levels [166]. Cardiac and skeletal muscle require tight regulation of voltage-gated calcium
channels and calcium homeostasis to coordinate the excitation-contraction coupling process [170].
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Phosphatidylinositol (4,5) bisphosphate (PIP2), a phospholipid component of cell membranes,
serves as an important regulator for Ca2+ release from the sarcoplasmic reticulum and assists in the
maintenance of normal calcium signaling to control contractile forces [167,168,171]. The fatty acids of
PIP2 are variable in different species and tissues, but studies show the most common fatty acids are
stearic in position 1 and ARA in position 2 [37].
Calcium homeostasis, regulation and maintenance are critical elements for normal muscle
function. Wolf et al. [34] have shown that the endoplasmic reticulum is directly responsible for
the regulation of intracellular Ca2+ concentrations. ARA plays an important cooperative role with
myo-inositol 1,4,5-triphosphate (IP3) in glucose-induced calcium mobilization and insulin secretion by
pancreatic islets.
PIP2 and phosphatidylinositol 3,4,5-triphosphate (PIP3) are also critical for cardiac function [172].
In the heart, PIP2, as a key second messenger, controls the activity of ion channels involved with
the modulation of heart rhythm. PIP3, on the other hand, is primarily involved in the control
of cardiomyocyte apoptosis, hypertrophy, and contractility [172]. In adults, deregulation of the
phosphoinositide metabolism is associated with the onset and progression of several cardiovascular
pathologies including atherosclerosis and heart failure [172].
Muscle growth and atrophy depend on the balance between the rates of protein synthesis and
degradation [173]. In vitro experiments with animal and human skeletal and cardiac muscle tissue
indicate that prostaglandins are involved in the regulation of protein synthesis and degradation in
various types of striated muscle [173,174]. While PGE2 increases degradation of muscle in young rats
and causes net protein balance to become more negative, PGF2α causes a large stimulation of protein
synthesis in muscle tissue [173]. These findings are consistent with the many important roles played
by prostaglandins PGE2 and PGF2α in muscle protein balance and indicate that overall, ARA serves
multiple functions in cardiac and skeletal muscle function and physiology.
8. Biomagnification and Accretion of ARA in Infants
Biomagnification is when infants have higher levels of LCPUFA in plasma lipid fractions and
erythrocytes as compared with their mothers [45]. Biomagnification can be especially marked for ARA
with levels more than 2-fold of that from the maternal side and independent from the amount of its
precursor LA available maternally. The stability of LA content implies that any conversion to ARA
is not keeping up with the fetal demand for ARA [45]. Biomagnification by the placenta serves to
preferentially obtain preformed ARA and DHA from the mother in order to deliver it to and nourish
the fetus [45].
As shown by Kuipers et al. [175], biomagnification is independent of maternal ARA status at both
delivery and at 3 months of age and is found to be similar across different populations with differing
diets. These findings indicate that biomagnification as a biological process seeks to achieve a uniform
ARA status in infants at the expense of their mothers. The process of biomagnification suggests that
a certain level of infant prenatal ARA status must be maintained for optimal infant growth.
Infants with the lowest birthweights have the lowest levels of ARA, and those born earliest have
the lowest levels of DHA [45]. The process of biomagnification initially protects vascular growth
which is a requirement for brain growth. Vascular growth must precede brain growth to meet the
brain’s demand for energy, which can be as high as 70% of the total fetal demand for energy in the last
trimester of pregnancy [45].
At delivery, as shown by Luxwolda et al. [176], the maternal RBC-ARA content is consistently
higher than that at 3 months postpartum. At delivery, infant RBC-ARA content is similar or higher
than their mother’s RBC-ARA contents. From delivery to 3 months postpartum, maternal RBC-ARA
increases while infant RBC-ARA decreases. The decrease in RBC-ARA content may be due to a lower
conversion of LA to ARA since the infant’s capacity to synthesize LCPUFA decreases dramatically
after delivery [69] and has been shown to decrease with gestational age at birth [64].
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There appears to be a tightly regulated synergism between DHA and ARA at low DHA status
and an antagonism at high DHA status [50]. Intrauterine DHA biomagnification in mothers with low
fish intakes aims at a synergistic increase of fetal DHA to maintain a balance with ARA. Bioattenuation
at higher DHA status may in turn prevent abundant passage of DHA across the placenta that leads to
antagonism with ARA. Since ARA is important for fetal growth [177] and is rapidly accreted in the
fetal brain [178,179] any competition from gestational DHA must be tightly regulated and balanced
for optimal neurodevelopment after birth [50]. Dietary depletion of ARA in early infancy may have
adverse consequences for brain development [178,179].
9. Consequences of ARA Deficiency
Essential fatty acid (EFA) deficiency impairs lipid and energy metabolism, cell membrane
structures, lipid signaling pathways, and ultimately leads to death [180,181]. Mammals are dependent
on a dietary supply of LA and ALA which are converted into n-6 and n-3 PUFA, respectively. ∆6-fatty
acid desaturase (FADS2) converts LA to γ-linolenic acid (C18:3n-6) and ∆5-fatty acid desaturase
(FADS1) converts dihommo-γ-linolenic acid (C20:3n-6) to ARA [182].
Early studies of EFA deficiency considered the effect that various dose levels of intake of LA,
ARA and ALA esters (0% to 10% of total calories for 100 days) had on the fatty acid composition in
the liver of rats [183]. Fat deficiency symptoms (necrotic tail and scaly feet) appeared in all animals
fed LA at less than 0.6% of calories and ARA at less than 0.25% of calories. ARA was 3-fold more
effective than LA in liver incorporation and mitigating deficiency. Fat deficiency symptoms affecting
the skin were not surprising. In the skin, as in all organs, EFA are principally found in glycolipids
and phospholipids. Most of the epidermal fatty acid PUFA is ARA [184]. EFA deficiency causes skin
flaking in humans, dogs, and mice, symptoms that can be restored with LA dietary therapy [184].
Since LA deficiency results in disruption of the skin’s water barrier function [185] and heat
loss from skin [186] the side effects make it difficult to distinguish the specific effects of ARA
deficiency independent from those related to LA deficiency. The fads2´/´ mouse allows for the
specific investigation of ARA deficiency without the underlying complications of LA deficiency [181].
The mutation eliminates ∆-6 desaturase activity leading to a dramatic decrease in the accumulation of
ARA in tissues and subsequently, ARA conversion to PGE, TXB, prostacyclin and leukotrienes. Platelet
aggregation and thrombosis are therefore also limited.
When fads2´/´ mice were followed for several weeks and fed a diet lacking ∆6-fatty acid
desaturase products but containing ample amounts of LA, the lack of PUFA and eicosanoids did
not impair lifespan but all the mice were sterile, developed ulcerative dermatitis, splenomegaly, and
ulceration in the duodenum and ileocecal junction [182]. Liver levels of ARA and DHA declined by
95% and somewhat smaller decreases were observed in the brain and testes (~50%). The absence
of γ-linolenic conversion in the fads2´/´ mouse deprived the cyclooxygenase and lipoxygenase
pathways of their substrates, including the elimination of PGE synthesis, the failure of synthesis
of TXBs by thrombocytes, and the failure to produce leukotrienes [181]. PUFA supplementation
completely restored the adverse symptoms observed in fads2´/´ mice. The mechanism by which
ARA prevented dermatitis may be due, at least in part, to lower levels of prostaglandin D2 (PGD2)
when skin ARA is decreased [182].
The ulceration of the small intestine in the fads2´/´ mouse may have been associated with
the decline of prostaglandin synthesis, similar to the effect often seen with the long-term use of
NSAIDs [187]. NSAIDs block prostaglandin synthesis by inhibiting cyclooxygenases, leading to
an erosion and then ulceration of the mucosal layer of the stomach and small intestine. However,
loss of organized stratification of proliferating cells into defined zones is a common feature of EFA
deficiency [188].
The ∆6-fatty acid desaturase gene FADS2 was cloned in 1999 [189]. An adult human case of
∆6-fatty acid desaturase deficiency was identified and described in the literature [190]. The patient
exhibited growth retardation accompanied by skin abnormalities, corneal ulceration, and feeding
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intolerance. Treatment with dietary DHA and ARA restored normal growth and eliminated most of
the symptoms [190].
A novel genetic model, the FADS1 (∆5 desaturase) knockout mouse was used to determine the
role that the ARA-derived 2-series eicosanoids had in mucosal physiology and inflammation [191].
Fads1´/´ mice have very low levels of ARA in tissues (colon mucosa, liver, spleen, serum and fatty
acid profiles). The deficiency in ARA resulted in a massive enhancement of dihomo-y-linolenic acid,
the 1-series prostaglandin substrate in tissues and a decrease in 2-series-derived prostaglandins or
PGE2. Fads1´/´ mice failed to thrive, gradually dying at 5 to 6 weeks of age with no survivors past
12 weeks of age [191]. The lack of PGE2 was associated with disturbed intestinal crypt proliferation,
altered immune cell homeostasis, and a heightened sensitivity to acute inflammatory challenge [191].
Dietary supplementation with ARA extended the longevity of fads1´/´ mice to levels comparable
with normal wild-type mice (Figure 6).
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that contained 3.7% ALA and 16% LA with or without 1.2% ARA and/or 1.2% DHA  for 18 days 
immediately after birth [192]. Compared with wild‐type mice, the body weight of the mice fed the 
control diet was significantly  lower, particularly after 6 weeks of age. However, body weights of 
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Figure 6. Kaplan-Meier survival curves of Fads1 mice, AA = ARA. (A) Fads1 null mice exhibited low
viability when fed a standard AA-free diet; n = 37 for wild-type, n = 44 for heterozygous, n = 11 for
Null; (B) Dietary supplementation with AA (0.1% and 0.4%, w/w) partially reversed the Fads1 null
mouse phenotype; n = 5 for Null + 0.1% AA, n = 3 for Null + 0.4% AA. Supplementation with 2.0% AA
completely reverse the Null phenotype; n = 4 for Null ˘ 2% AA (from Fan et al. [191]).
Although fads1´/´ and fad2´/´ mice are useful to examine the function of ARA in vivo PUFA
are transferred through the placenta from the heterozygous mother into the homozygous fetus.
Additionally, the amount of DHA and ARA in the brain tends to remain tightly controlled even
under conditions of PUFA deprivation, but at the expense of other tissues to protect the brain [182].
Lpiat1´/´ mice have a mutation that affects the synthesis of ARA-containing PI. PI is unique in its
fatty acid composition, i.e., most of the fatty acid that is attached to the sn-2 position of PI is ARA [33].
Other membrane phospholipids such as PC and PE contain other PUFA including DHA.
Lee et al. [33] showed that Lpiat1´/´ mice had a reduced content of ARA in PI and had deficits in
cortical lamination during brain development, delayed neuronal processes in the cortex, and reduced
neurite outgrowth in vitro. Lpiat1´/´ mice died within a month and showed atrophy of the cerebral
cortex and hippocampus. These results demonstrate the importance of ARA-containing PI in normal
cortical development in mice. By eliminating LPIAT1 in Lpiat1´/´ mice, the enzyme responsible
for the incorporation of ARA into PI, it was shown that the ARA-containing PI is essential for brain
development in mammals [33].
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Newborn pups of ∆6-fatty acid desaturase knockout mice were administered artificial milks
that contained 3.7% ALA and 16% LA with or without 1.2% ARA and/or 1.2% DHA for 18 days
immediately after birth [192]. Compared with wild-type mice, the body weight of the mice fed the
control diet was significantly lower, particularly after 6 weeks of age. However, body weights of
knockout mice fed milks with DHA and ARA+DHA were similar to that of the wild-type mice. Motor
activities of the knockout mice fed ARA were elevated compared with the wild-type mice and those fed
the control diet. Better motor performance was also observed in knockout mice fed the ARA + DHA
diet. The authors concluded that ARA corrected the decrease in body weight and the combination of
ARA and DHA improved the motor dysfunction caused by the deficit of ∆6-fatty acid desaturase.
Taken together, results from these investigations indicate the importance of ARA and its
derivatives for the coordination of cellular differentiation, organogenesis, and function during early
growth and development.
10. Animal Studies of ARA Supplementation
10.1. Immunomodulatory Effects of ARA and DHA Supplementation
The activation of peroxisomal proliferator-activated receptors (PPARs) has been shown to be
protective in brain ischemic and oxidative injury and in many neurological diseases that may affect
infants [193] (Figure 7). In addition, transcription of the gene for the Major Facilitator Superfamily of
the domain-containing protein 2a (MFSD2A) has been identified as being an important transporter for
the uptake of DHA across the blood brain barrier [194] and is under the control of PPAR [195]. Studies
indicate that LCPUFA and their metabolites are ligands to PPARs. Diets containing an n-6:n-3 ratio
of about 1-2:1 supplied during pregnancy and lactation appear to be optimal for the expression of
neuron-specific enolase, glial fibrillary acidic protein and myelin basic protein, markers related to the
growth and maturation of neurons, astrocytes and myelin [193].
To investigate the immunomodulatory effects of different PUFA, weanling rats were fed a high-fat
diet (178 g/kg) that contained 4.4 g of ALA, γ-linolenic, ARA, EPA, or DHA/100 g total diet [196] for
6 weeks. The proportion of total PUFA content (~35 wt %) was held constant and the n-6 to n-3 ratio was
maintained at 5.8 to 7.0. PGE2 production was enhanced in leukocytes from rats fed the ARA-rich diet
and was decreased from leukocytes in rats fed the EPA or DHA diets. ARA did not affect lymphocyte
proliferation, NK cell activity, or the cell-mediated immune response. Lack of an effect on T-lymphocyte
proliferation and Con A in splenocyte cultures was also observed in mice fed a safflower oil ethyl ester
diet +1% ARA for 10 days [197]. The lack of an immunological effect of ARA agrees with findings
from a human study that considered 1.5 g of ARA/day for 50 days on the proliferation response
of peripheral blood mononuclear cells to Con A, phytohemagglutinin, or poke-weed mitogen [198].
Human peripheral blood NK activity was also unaffected by the consumption of ARA.
Prostaglandins which are involved in inflammatory processes also play a major role in the recovery
of intestinal barrier function in ischemia-injured porcine ileum by converting ARA to PGH2 [199].
The importance of ARA and ARA-derived eicosanoids in the intestinal epithelium was reviewed by
Ferrer and Moreno [200]. In a study that considered the effect of supplemental ARA on intestinal
barrier repair in ischemia-injured porcine ileum pigs were fed a formula containing no LCPUFA
(0% ARA), 0.5% ARA, 5% ARA, or 5% EPA for 10 days. Piglets that were fed 5% ARA exhibited
enhanced recovery compared with piglets fed 0% ARA or 0.5% ARA [201]. The EPA-fed piglets had
enhanced recovery comparable with piglets fed 0% ARA. The enhanced recovery response observed
with 5% ARA was supported by reduction in the mucosal-to-serosal flux of 3H-mannitol and 14C-inulin
compared with the other dietary groups. Jacobi et al. [201] concluded that piglets fed a high-ARA diet
are less susceptible to ischemia-induced epithelial cell sloughing and that feeding elevated levels of
LCPUFA, including ARA, enhances acute recovery of ischemia-injured porcine ileum. For infants
affected by necrotizing enterocolitis (NEC) where physiological repair of the intestines is necessary
elevated LCPUFA intake including ARA enhances recovery of damaged tissues [201].
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Figure 7. Schematic summary of molecular events and functional outcomes involved in metabolism
of ARA. ARA is derived from endogenous synthesis or directly fr m the diet and is corporated
into cellular membran compl x lipids. Within the lipi bila e , ARA is nriched in PE and PI in
th inner embrane. Coordination of spatial-temporal interaction betwe n molecular and cellular
compone ts and activities are medi ted by metabolites of, or molecules associat d with metabo ism
of ARA. Metabolism of ARA is triggered by activation f transmembrane receptors as a result of
binding a ligand. A few examples of rec ptor-mediated activation of ARA metabolism include glucose,
vitami D3, C 2+, or antigen presentation or detection by immune cells. ARA r leased from the
membrane by the actions of PLA2 or metabolized by enzymes such as COX, CYP450, and/or LOX can
act directly or serve as a substrate for various enzymes to produce second-messengers. ARA-derived
eicosanoids, including prostaglandins, leukotrienes, lipoxins, and HETEs regulate numerous activities
including passage of ions between subcellular compartments, interactions between various structures
or cells, and nuclear regulation of gene transcription by PPARs activators. Within the inner leaflet
of cell membranes, ARA is enriched in micro-domains and is involved in regulation of receptor
mediated activities. In addition, micro-domains serve as foundations for biophysical interactions
between subcellular structures such as microtubules and other cytoskeletal activities including vesicular
transport. The consequences of temporal-spatial regulation include coordinated release of hormones,
expression of various cell functions, and/or alterations in phenotypes, and cellular motility. Examples
of PPAR-regulated gene products involved tissue uptake of LCPUFA and oxidation of stored lipids:
MFSD2A, major facilitator of superfamily domain-containing protein 2A. Membrane components:
Chol, cholesterol; Gang, gangliosides; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI,
phosphatidylinositol; PS, phosphatidylserine; SPM, Sphingomyelin. Nuclear transcription factors:
PPAR, peroxisome-proliferator activator receptors; RXR, retinoid X receptors. TM, transmembrane
receptors. Enzymes: COX, cyclooxygenase; CYP450, cytochrome P450; LOX, lipoxygenase; PLA2,
Phospholipase A2; PLC, Phospholipase C. Signaling molecules: PG, prostaglandin (Adapted from
Pike [32]).
EFA deficiency also leads to hepatic steatosis. When rats were administered varying amounts of
DHA and ARA to determine whether exclusive supplemen ation with DHA or ARA could prevent
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EFA deficiency and inhibit the development of hepatic steatosis mice fed at least 2% of their calories
from DHA and 1% of the calories from ARA did not develop clinical or biochemical evidence of EFA
deficiency disease or hepatic steatosis [202]. Although hepatic steatosis is an adult disease, the fact
that mice fed at least 2% of their calories from DHA and 1% of the calories from ARA prevent the
development of EFA deficiency suggests the importance of ARA throughout the lifespan.
To investigate the ability of ARA- and ARA + DHA-enriched formula to modulate immune
response in neonatal piglets to an inactivated influenza virus vaccine Bassaganya-Riera et al. [203]
considered a diet with ARA + DHA in sow milk fed at birth. The diet modulated antigen-specific
T-cell responses to an inactivated influenza virus and up-regulated IL-10 expression [203]. Although
ARA and DHA have been suggested to elicit opposing immunomodulatory actions, the immunologic
outcome in the study was beneficial [203]. The authors concluded that ARA + DHA enriched formulas,
with the approximate 2:1 ratio fed during the neonatal period, may prevent or manage autoimmune
and allergic reactions in infants by down-modulating T-cell reactions.
10.2. Retinal and Neurodevelopmental Effects of ARA and DHA Supplementation
The retinal DHA content in guinea pigs was considered in relation to diets containing different
n-6:n-3 ratios (from 72.0 to 2.5) [204]. Not surprisingly, diets with the highest n-6:n-3 PUFA ratios
had the highest n-6 retinal fatty acid profiles. Weisinger et al. [204] reported that retinal function was
altered by tissue DHA levels and responded according to an inverted “U-shaped” function. As DHA
levels increased past an optimal amount found to be 19%, the result was poorer electroretinographic
scores. However, there was no mention that as DHA increased there was a corresponding decrease in
ARA levels due to ARA antagonism. The marked decrease in ARA levels may have been the variable
of interest that was not fully considered and responsible for the electroretinographic changes at high
DHA intakes.
Champoux et al. [205] used a neurodevelopmental battery to test the neurological behavior in
rhesus macaques neonates fed a control formula without LCPUFA or a LCPUFA-supplemented formula
with 1 wt % each of DHA and ARA. Macaque neonates fed the supplemented formula obtained higher
scores on motor maturity and orientation than those fed a control formula. Champoux et al. [205]
concluded that the results supported the view that preformed DHA and ARA in infant formulas are
required for optimal neurological development.
Learning behavior in rats fed a diet supplemented with 3% safflower oil (Safflower, n-3 fatty acid
deficient, high LA acid) was compared to those fed 3% perilla oil (Perilla, high ALA) [206]. Through
two generations, the n-3 fatty acid deficient group exhibited decreased correct response ratios in
a brightness-discrimination behavior test. The altered learning ability in the brightness-discrimination
test was restored with supplementation of DHA after weaning, only after levels of ARA in the brain
lipids were normalized. The authors concluded that n-3 fatty acid is essential for the maintenance
of learning performance and that n-3 deficiency in the presence of n-6 fatty acid during gestation
did not lead to irreversible damage to the brain [206]. Thus, both DHA and ARA affected learning
performance and a balance of ARA and DHA levels must be maintained.
To investigate the effects that varying dietary levels of LCPUFA have on growth, brain fatty
acid composition and behavior in mice, 5 groups of pregnant and lactating mice were fed diets with
either very high n-6 to n-3 ratio of 49 (n-3 deficient), a more usual ratio of 4.0, or a low ratio of 0.32
for 15 weeks [207]. There was no effect of diet on birth weights of pups, but on days 15 and 22 the
pups in the low n-6 to n-3 groups weighed less than those in the other treatment groups. Increasing
levels of DHA in the diet increased brain DHA and decreased brain ARA. The differing ratios of n-6
to n-3 had no effect on the ability of mice to learn the place test or perform in the Morris water maze.
However, the mice fed the low n-6 to n-3 ratio swam more slowly, unless ARA was substituted for LA
as the source of the n-6. The lower body weight in the high n-6 to n-3 fed mice was not attributed to
simply n-6 deficiency. The high n-3 to n-6 ratio led to the inhibition of ∆6-desaturase [207]. Thus, the
conversion of LA to ARA was impeded and ARA became unavailable for growth. Mice fed high levels
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of DHA also had high levels of EPA showing a considerable amount of retroconversion. The findings
showed the importance of balancing the amounts of ARA to DHA and that some deficits can be
overcome if LA is replaced by ARA as the source of n-6 fatty acid [207]. Wainright et al. [208] also
reported that ARA supplementation increased ARA levels and decreased DHA levels in forebrain
membrane phospholipids in Long-Evans rats, whereas DHA supplementation increased DHA levels
and decreased ARA levels. Correlational analyses did not show a relationship between DHA and ARA
levels in the forebrain and working memory performance [208,209].
Newborn infants of diabetic mothers have lower ARA and DHA levels in cord blood than
newborns of normal mothers [210]. The lower levels of the LCPUFA in the newborns of diabetic
mothers were associated with impaired and altered sensory-cognitive and psychomotor functions
at birth and reduced visual and memory performance at 8 and 12 months [211,212]. Compared
with normal controls, most rat models of diabetes are characterized by a lower level of brain ARA
only and not a lower level of DHA [213]. Even though both ARA and DHA are important for
neurodevelopment, brain accretion of ARA exceeds that of DHA during gestation [214], especially in
the first two trimesters during the period of rapid proliferation of neuronal and glial elements [179,215].
When Sprague-Dawley diabetic, pregnant rats were fed either a control diet or an ARA (0.5%)
supplemented diet throughout reproduction, the weaned offspring in the ARA group performed
significantly better in the water maze and rotarod tests and showed greater exploratory behavior
than control-diet offspring [216]. The results indicated that maternal hyperglycemia has long-term
consequences during the initial stages of learning and that maternal supplementation with ARA
positively influences learning outcomes.
Amusquivar et al. [217] reported that rat pups of dams fed diets with n-3 fatty acids from fish oil
compared with those fed n-6 fatty acids from olive oil during pregnancy and lactation had smaller
increases in postnatal body weight and length, and delayed body and psychomotor maturation indices.
Slower growth and brain development occurred when both dams and fetuses were fed a moderate
amount of fish oil (10%) as the only fat source [217]. In the study, the ARA level was lower than
the DHA level in brain tissue of the offspring of dams fed high n-3 fatty acid diets. The differences
in postnatal development disappeared when the fish oil was supplemented with γ-linolenic acid,
a precursor of ARA. The growth deficits were also eliminated by the inclusion of ARA in the diet [207].
The studies demonstrate the importance of maintaining adequate levels of ARA during development,
and suggest that diets too high in n-3 fatty acids during development may have negative effects on
development by reducing tissue levels of ARA [218].
To investigate the effects that a DHA-rich maternal diet compared with an ARA-only diet have
on brain fatty acid composition of Sprague-Dawley rats, Elsherbiny et al. [219] considered a control
diet containing ARA (0.4 g/100 g of total fatty acid) vs. a DHA + ARA diet (0.9 g/100 of DHA and
0.4 g/100 g of ARA of total fatty acid). The results indicated that at three weeks postnatally the
DHA-rich diet increased levels of DHA in the brain and decreased ARA by 12.8%. The brain of
a three-week-old rat is at a comparable stage as that of a human toddler at 2–3 years of age [219]. At six
weeks (comparable to a 12–18 years old human), the DHA-induced decreases in ARA were reversed
and disappeared when DHA was continued (i.e., DHA/control group). Thus, elevated dietary levels
of DHA decrease the amount of ARA in brain without an adequate supply of dietary ARA.
Prepulse inhibition (PPI) is a normal suppression of a startle response when a low intensity
stimulus that elicits little or no behavioral response immediately precedes an unexpected stronger
startling response [220]. Deficits in PPI have been reported in individuals that have mental disorders
including schizophrenia [220]. Various brain regions including the hippocampus have been associated
with PPI problems. To determine whether dietary administration of LCPUFA enhances neurogenesis in
the rat hippocampus and improves PPI response in wild-type mice and Pax6+/´ mice (that exhibit PPI
deficits) a control diet or diets supplemented with ARA (4%), DHA (4%) or ARA (4%) + DHA (4%) were
administered [220]. Compared with the other diets, the administration of the ARA diet successfully
increased neurogenesis not only in the Pax6+/´ mice but also in the wild-type mice. Treating the
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Pax6+/´ mice with ARA also resulted in alleviating their PPI deficits. The authors suggested that the
ARA diet as compared with the DHA or ARA + DHA diets positively affected postnatal neurogenesis
in several regions of the brain including the hippocampus by influencing the fluidity of neuronal
membranes and by regulating neuronal transmission [220].
11. Introduction of DHA and ARA in Infant Formulas
Both DHA and ARA have been added to infant formulas in the United States since 2001. In Europe,
the addition of DHA and ARA in infant formulas began much earlier in 1994. Most infant formulas
contain 0.2% to 0.4% total fatty acids of DHA and between 0.35% and 0.7% total fatty acids of ARA
based on worldwide averages of DHA and ARA content in human milk [5]. Several international
expert groups [6–9] support the addition of these levels of DHA and ARA in infant formulas to ensure
optimal infant growth and development. Thus, all commercially available infant formulas contain
preformed ARA at levels equal to or higher than the DHA content in formulas where these LCPUFA
are added.
To determine the necessity of adding LCPUFA to infant formula, several studies were performed
in the 1990s with preterm and term infants fed formulas containing DHA or EPA with and without ARA
(see Fleith and Clandinin [221] for a review). No studies have examined supplementation of infant
formula with ARA alone. In most studies, a control group without LCPUFA and/or a breastfed group
were included. Studies also investigated the effect of adding ALA to ensure a sufficient endogenous
synthesis of DHA [222,223], but not surprisingly, due to the limited conversion of ALA to DHA,
the added ALA was not effective in raising DHA plasma status to the same level as that observed
in breastfed infants ([223]. Some studies also considered experimental formulas containing added
γ-linolenic acid from black current-seed oil, borage oil, or evening primrose oil, DHA and EPA from
marine oil, and ARA from egg phospholipids [223–229]. The effects of feeding formula supplemented
with soy oil and marine oils containing DHA/EPA showed no abnormalities on growth, tolerance,
clotting function, erythrocyte membrane fluidity and vitamin A or E levels in low-birth-weight-term
infants [230].
Infant formulas containing DHA and ARA from single cell oils (DHASCO® and ARASCO®, DSM,
Columbia, MD, USA), respectively, were evaluated and found to maintain both DHA and ARA status
in infants [178,231–233]. After 2001, DHASCO and ARASCO (DSM, Columbia, MD, USA) became
predominant as the sources of DHA and ARA added to infant formulas in the United States. Both
DHASCO and ARASCO are general recognized as safe (GRAS) for use in infant formulas in the United
States and approved as novel foods in Canada [234,235]. DHASCO and ARASCO have an established
history of use in Europe, Australia and New Zealand and are not considered novel foods and can be
added to infant formulas (see Ryan et al. [236] for a review of the safety of single-cell oils).
The clinical studies used to evaluate the effects of DHA and ARA added to infant formulas
measured infant growth, body and fatty acid composition, behavioral and sensory functions (retinal
function, visual acuity and auditory function). Many of the early studies focused on preterm infants
because they provided an opportunity to evaluate the effects of DHA- and ARA-enriched formulas
in infants who may be deficient in these LCPUFA. Transfer across the placenta and accretion of
ARA and DHA in the developing human brain and retina occurs mainly during the last trimester
of pregnancy [179,215] when the rate of brain growth is most rapid [237]. Infants born prematurely
thus may have an increased need for dietary ARA due to the interrupted supply during the last
trimester [220,238,239].
Four studies with preterm infants considered formulas without added preformed ARA [240–243].
Each was influential in recognizing the importance of ARA for optimal growth. Two of the studies
reported an increase in visual acuity at 2 or 4 months postmenstrual age (PMA) in preterm infants fed
formulas supplemented with DHA and EPA from fish oil with a low or high ratio of DHA to EPA (2:1,
5:1, respectively) and no ARA [241,244–246].
Nutrients 2016, 8, 216 24 of 47
In one study [240], infants fed formula with a low ratio of DHA to EPA until 79 weeks
PMA, compared with controls, had significantly lower z-score values for weight, length and head
circumference beginning at 40 weeks PMA. Poorer growth was also associated with lower scores of
psychomotor development [244]. The supplemented group also had lower blood levels of ARA [177]
suggesting that the effects of growth may have been related to the reduced availability of ARA as
a result of the competitive inhibition by the high levels of EPA in marine oil. This finding was supported
in a second study [241] in which preterm infants were fed formula with a high DHA to EPA ratio until
48 weeks PMA. Compared with controls, preterm infants fed a high ratio of DHA to EPA and with no
ARA consistently had lower mean weight-for-length values at 2, 6, 9, and 12 months PMA, weighed
less at 6 and 9 months PMA, and had smaller head circumferences at 9 months PMA [246].
In a third study, three premature infant formulas were compared in a double-blind parallel-group
study of the growth of healthy, very-low-birth-weight infants (846–1560 g at birth) [242]. The DHA
formula contained 0.34% of fat as DHA and the DHA +ARA formula contained 0.33% as DHA and
0.60% as ARA. The control formula contained no DHA or ARA. A reference group consisted of
term infants who were predominately breastfed. Results indicated that infants fed formula with
DHA + ARA gained significantly more weight than infants fed formula without DHA+ARA. At 48
and 57 weeks, weight of infants in the DHA + ARA group did not differ from the reference group of
term infants. Length of infants in the DHA + ARA group was significantly greater than that of infants
fed DHA alone at 40 and 48 weeks, but not at 57 weeks. The authors concluded that supplementation
with ARA in addition to DHA supported growth of preterm infants [242].
In a fourth study [243], male but not female preterm infants fed formula with DHA and EPA from
fish oil (0.2 wt %, 5:1 ratio) and no ARA, or a control formula to 59 weeks PMA, had significantly
smaller gains in weight, length, and head circumference and lower fat-free mass as determined from
total body electrical conductivity (TOBEC).
In the Carlson et al. [177,240] studies that reported slower growth in preterm infants a positive
association between plasma ARA concentration and measures of growth (weight, length, z-score,
weight-to-length, and head circumference) was observed. In the 1990s, when the studies were
conducted, it was unknown whether the negative effects of DHA and/or EPA supplementation
on growth could be overcome by adding ARA to infant formulas [177]. However, it was known that
the bioactive metabolites of ARA mediate the secretion of several hormones associated with growth
and basic metabolic functions [247]. These include luteinizing hormone, prolactin, adrenocorticotropic
hormone (ATCH), and corticotropin-releasing hormone (CRH) [241] which could influence growth.
ARA and its second messengers also appear to be involved in bone formation and resorption [248].
To maintain ARA status in preterm infants, additional studies were performed with infant
formulas containing both ARA and DHA [221]. The addition of ARA at levels found in breast milk
produced growth comparable to that observed in breastfed infants [221]. Adding both ARA and DHA
to preterm infant formulas also resulted in beneficial effects on visual acuity as compared with infants
fed a control formula [221].
Concern with a high level of DHA without a concomitant increase of ARA was raised in
a randomized, controlled clinical trial of term infants administered formula with no LCPUFA, or
differing levels of DHA intakes of 0.32%, 0.64% and 0.96% at the same ARA level of 0.64% [249,250].
There were no formula effects on tests of behavioral and psychophysiological indices of attention
at 4, 6, and 9 months of age. However, infants supplemented at the two lower doses of DHA spent
proportionately more time engaged in active stimulating processes (increased attention) than infants
in the unsupplemented group [249]. Positive results were also observed on vocabulary (Peabody
Picture Vocabulary), a card-shorting task, and an intelligence test (Wechler Primary Preschool Scales of
Intelligence) at 3 to 6 years of age in the two lower doses of DHA (0.32% and 0.64%) [250]. However,
performance of infants and children who were administered the highest dose of DHA (0.96%) but with
a reduced ratio of ARA to DHA was attenuated [250]. The results demonstrated that a proper balance
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of DHA and ARA is needed for optimal cognitive performance as too much DHA may suppress the
benefits provided by ARA.
The effects that different ratios of n-6 to n-3 had on preterm infant neurodevelopment were
recently considered by Alshweki et al. [251]. Preterm infants (<1500 g and/or <32 weeks gestational
age) were given infant formula with an n-6 to n-3 ratio of 2:1 or 1:1. The infants were followed for up
to 2 years. Preterm infants fed formula with a 2:1 ratio of ARA to DHA had higher ARA blood levels
during the first year of life and better psychomotor development compared with those fed a 1:1 ratio
of ARA to DHA. However, despite the fact that one group received twice the amount of ARA than
DHA (66% vs. 33%), there was almost no difference between the two groups in plasma n-6 to n-3 ratio.
The balance between n-6 and n-3 is very complex, but appears to be maintained at a steady level when
adequate supplementation of ARA and DHA are available [251].
To date, several systematic reviews of the literature and meta-analyses have been published
to evaluate the effects of LCPUFA in preterm and term infants [221,229,252] on various outcomes
including growth, cognition and vision. The reviews considered both the earlier and more recent
studies on LCPUFA. Fleith and Clandinin [221], in one of the earliest reviews, reported that collectively
the body of literature supported the view that LCPUFA are important for growth and development of
preterm and term infants. Formula levels of ARA and DHA should be in the same range as those found
in human milk and with the same ratio [221]. There needs to be a dietary supply of ARA and DHA to
achieve similar accretion levels in plasma and in RBC as compared with breastfed infants [221,253,254].
A Cochrane review of LCPUFA supplementation in term infants reported that there was
little evidence that supplementation conferred a benefit on visual or cognitive development [229].
In a recent meta-analysis of four clinical trials including data for preterm and term infants, LCPUFA
supplementation was also shown to have no effect on Bailey Developmental scores at 18 months
of age [252]. However, as pointed out by Colombo et al. [250], the lack of an observed effect at
18 months of age is consistent with the view that the Bailey Scales of Infant Development are not very
sensitive to the effects of LCPUFA supplementation. The Bailey Scales of Infant Development yield
a composite score obtained from the infant’s attainment of normal developmental milestones and
may not be able to provide detailed assays of specific cognitive mechanisms that are measured using
more sophisticated laboratory tasks [250]. This raises the question of whether the Bailey Scales are
appropriate for measuring the effects of LCPUFA on cognitive development in older infants/toddlers.
A systematic review of 20 randomized, controlled trials of term infants who received DHA and
ARA supplemented formula or a control formula indicated that infants given formulas containing
DHA levels close to the worldwide human milk mean of 0.32% of total fatty acids were more likely to
yield positive results on cognitive and visual tests [255]. There was also clinical evidence to suggest
than an ARA:DHA ratio greater than 1:1 was associated with improved cognitive outcomes [255].
Since the publication of the Hoffman et al. [255] review, several epidemiological and interventional
studies of LCPUFA supplementation during infancy have appeared in the literature. These recent
publications have been reviewed by Ryan et al. [256]. The most recent data indicate that
maternal supplementation during pregnancy and/or lactation support the role for LCPUFA in
the neurodevelopment of infants [256]. Supplementation with LCPUFA-containing infant formula
for more than 6 months increased the likelihood of observing improved cognitive function during
infancy [256,257].
The reasons that some studies failed to show a statistically significant association between
LCPUFA intake and better neurological performance may have been related to limitations of study
design and the use of varying amounts and sources of LCPUFA. For example, in the United States, most
of the recent studies that have considered both neurocognitive function and growth have used infant
formulas for preterm and term infants that contain DHA and ARA from single cell oils (DHASCO®
and ARASCO®). Outside the United States, DHA may be obtained from fish oil [258,259] and ARA
may be obtained from eggs [260,261]. As mentioned above, the early studies of the 1990s used
a variety of experimental formulas with different sources and amounts of LCPUFA (many of these
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studies are cited by EFSA in their review, [71]). This is noteworthy because only DHA and ARA from
single cell oils have been recently shown to enhance neurodevelopment in both preterm [262–264]
and term infants [257,265]. The source of the oil is important because it significantly affects growth.
Clandinin et al. [264] have shown that body weight at 118 days and length at 79 and 92 weeks of age in
preterm infants fed formula containing ARA and DHA from single-cell oils were greater than in those
than those fed a formula containing DHA from tuna oil. Additionally, for both weight and length,
there were no differences between breastfed infants and those fed ARA and DHA from single-cell
oils [264]. The possibility that ARA and DHA derived from single-cell oils or fish oil have differing
effects on growth and neurodevelopment may also be due to the EPA at too high a level in fish oil and
its propensity to antagonize ARA [257]. An ARA:DHA ratio greater than 1:1 with up to 0.65% of ARA
of total fatty acids is associated with improved cognitive performance [255] and balances the potential
competition caused by high levels of DHA.
12. The Benefits of ARA for Infant Health
LCPUFA are not only important for growth and neurodevelopment, but recent studies have
shown that LCPUFA are also critical for infant health. In an early study, infants fed formula with ARA
and DHA developed significantly less stage II and III NEC than those fed a control formula but had
similar rates of bronchopulmonary dysplasia, septicemia and retinopathy of prematurity (ROP) [266].
In a recent retrospective cohort study of premature infants (<30 weeks gestation), the relationship
between fatty acid profiles during the first postnatal month and infant morbidity due to chronic lung
disease, ROP, and late-onset sepsis was analyzed [120]. Results indicated that fatty acid levels of DHA
and ARA declined rapidly with a concomitant increase in LA. While the decreased DHA level was
associated with increased risk of chronic lung disease, decreased ARA was associated with increased
risk of late-onset sepsis. The authors noted that in premature infants, low levels of DHA and ARA
contribute to dysregulation of immune and inflammatory responses, predisposing these infants to
chronic lung disease and late-onset sepsis [120]. The DHA-derived resolvins decrease neutrophil
infiltration and enhance macrophage phagocytosis [267]. DHA also downregulates nuclear factor kB
activity in cells either directly or by stimulating the activation of peroxisome proliferator-activated
receptors thereby limiting the pro-inflammatory signaling mediated by ARA [267]. Thus, a low level
of DHA would predispose these infants to an increased inflammatory response as seen in chronic
lung disease. In late-onset sepsis, a decreased ARA level increases the risk of inhibiting the innate
immune response through decreased production of eicosanoids, particularly leukotrienes, which
enhance chemotaxis of leukocytes, neutrophil activation, and activity of natural killer cells [97,120].
As a consequence, in premature infants, a balance of DHA and ARA levels must be maintained to help
reduce the development of morbidity due to prematurity.
Studies have demonstrated that LCPUFA in human milk can modulate immunological responses
and affect the T-helper cell (Th) type-1 (Th1)/Th2 balance [268,269]. Th1 cell effectors produce
interferon-γ (IFN-γ) and TNF-α which regulate cellular immunity against infection whereas Th2
cells produce interleukin (IL)-4, IL-5, and IL-13 which help mediate immunity against parasitic
infections [270,271]. For example, Barakat et al. [272] reported that supplementation for 14 days
with 10 mg/kg of ARA in Schistosoma mansoni-infected schoolchildren induced moderate cure rates
(50%) in children with light infection and modest cure rates (21%) in those with high infection.
The cure rates associated with ARA were comparable to those produced by 40 mg/kg of praziquantel.
The combination of ARA and praziquantel elicited 83% and 78% cure rates in children with light and
heavy infections, respectively [272].
The relationship between maternal fatty acid desaturase (FADS) genotype and LCPUFA levels
in human milk on infant blood T-cell profiles and cytokine production in 6-month old infants was
recently considered [271]. LCPUFA levels in human milk were measured at 4 weeks of age and the
FADS genotype was determined in both mothers and infants. Results indicated that ARA levels in
human milk were inversely correlated with the production of the cytokines IL-10, IL-17, IL-5 and IL-13
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and EPA levels were positively associated with counts of regulatory T-cells and cytotoxic T-cells and
decreased T-helper cell counts. The minor FADS alleles were associated with lower ARA and EPA
levels in human milk and a higher production of IL-10, Il-17, and IL-5. The major FADS alleles were
associated with an increase in the level of ARA in human milk (19%–22%) compared with the minor
alleles. There were no association between T-cell distribution and maternal or infant gene variants.
Also, there was no relationship between cytokine levels in plasma and levels of LA, EPA, or DHA in
human milk.
It has been shown that the FADs gene polymorphism may influence the risk of developing
allergies in children [273]. In the study by Muc et al. [271] the strongest association between LCPUFA
levels and cytokines was observed among those related to the activity of type-2 and type-17 vs. those
from type-1 responses. The expression of type-2 and type-17 cells have been linked to increased airway
inflammation in severe asthma [274]. By reducing type-2 and type-17 activity, LCPUFA including ARA
found in human milk may help reduce the risk of childhood asthma and allergies [271].
Notably, Th17 cytokines were initially identified as key factors in the induction of inflammation
and tissue destruction associated with a variety of autoimmune response such as multiple sclerosis,
arthritis, colitis, celiac disease, and gluten sensitivity [275,276]. However, it is becoming apparent that
T17 cells also provide protective immunity against various pathogens at different mucosal sites [270].
Thus, there is a fine balance between protection and pathological manifestation of Th17 responses.
As a consequence, a balance of LCPUFA levels similar to that found in human milk is needed to help
reduce the risk of developing autoimmune diseases in childhood.
Two studies have compared the frequency of common illnesses in infants fed formula with and
without DHA and ARA [277,278]. Both studies used the same LCPUFA-supplemented formula that
contained 0.32% DHA and 0.64% ARA of total fatty acids (17 mg of DHA/100 kcal and 34 mg of
ARA/100 kcal). In the first study, infants fed the LCPUFA-supplemented formula experienced a lower
incidence of bronchiolitis/bronchitis compared with infants fed formula without DHA and ARA [277].
The results from the second study were similar to those of the first. Infants who consumed formula
with DHA and ARA had a lower incidence of bronchiolitis/bronchitis, nasal congestion, cough and
diarrhea requiring medical attention than infants fed formula without DHA and ARA. The authors
indicated that DHA and ARA at present levels in infant formula and follow-on formulas may have
a positive effect on moderate to severe common infant illnesses, including diarrhea [277,278].
Two cohorts of children who had previously completed randomized, double-blind trials (one
published [72], one unpublished) in which they received a LCPUFA-supplemented formula that
contained 0.32%–0.36% DHA and 0.64%–0.72% ARA of total fatty acids or an unsupplemented formula
(control) fed during the first year of life were followed up to 3 years of age to determine the incidence of
allergies and common respiratory illnesses [279]. The LCPUFA-supplemented group had a significantly
lower risk for developing upper respiratory infections, wheezing/asthma, atopic dermatitis, any
allergy, and a longer time to first diagnosis than those given an unsupplemented formula.
A subset of children from the Kansas City cohort of the DIAMOND (DHA Intake and
Measurement of Neural Development) study [96] were followed to 4 years of age to determine
the incidence of childhood allergies [280]. As infants, they were fed either a control unsupplemented
formula or one of three formulas with either 0.32%, 0.64% or 0.96% of total fatty acids as DHA with the
same amount of ARA (0.64% of total fatty acids). All the different DHA dose and ARA supplemented
subjects were pooled into a single supplemented cohort. Results indicated that the incidence of allergic
illnesses in the first year of life was lower in the combined LCPUFA group compared with the control.
By 4 years of age, LCPUFA supplementation significantly delayed time to first allergic illness and
skin allergic illness. LCPUFA supplementation also reduced the risk of any allergic diseases and
skin allergic diseases. If the mother had allergies, LCPUFA supplementation reduced the incidence
of wheezing/asthma in her offspring. The results of these allergy studies add to the evidence that
supplementation of infant formula with both ARA and DHA in the first year of life delays the onset of
allergy and may have a protective effect against allergy in early childhood.
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Crawford et al. [45] reviewed the potential role that ARA and DHA play in protecting against
some central nervous system injuries in preterm infants. Deficits of ARA and DHA may contribute to
the complications related to prematurity [45]. The mechanism of action responsible for central nervous
system injury is reduced vascular or endothelial integrity leading to hemorrhage or ischemia. ARA
acts as an endothelial relaxation factor and plays a dominant role in endothelial membrane lipids. The
inner cell membrane lipid of the endothelium is especially rich in ARA which provides for membrane
properties, signaling and protein kinase C activation [281]. ARA is also a precursor for a range of small
molecules that play a key role in cell trafficking, communication and vaso-regulation. As a result, any
ARA or DHA deficiency in very preterm infants will be exacerbated after birth during a period of
rapid growth. This deficiency may then lead to fragile, leaking vessels and rupture as seen in ROP [45].
The proportion of ARA the placenta delivers to the fetus ranges from 14% to 20% [45]. Infant
formula for preterm infants only delivers ~0.4%–0.6% of ARA. For DHA, the placenta delivery to the
fetus is ~6% whereas infant formula delivers ~0.3%. That is a 50-fold reduction in ARA and a >10-fold
reduction in DHA compared with the infant’s apparent physiological need. When plasma levels of
ARA and DHA are followed from birth, they continue to decrease to about one third of that of the fetus.
Crawford et al. [45] argue that higher intakes of ARA and DHA are needed to correct for deficiency
during the first year of life.
To explore the impact that deficiency of ARA and DHA may have on immune cell function
Moodley et al. [282] examined the fatty acid profile and main phosphoglyceride content of cord blood
mononuclear cell (CBMC) membranes in healthy preterm infants (30 to 35 weeks) and term infants
(37 to 40+ weeks). Results indicated that ARA was the dominant LCPUFA present in both PC and PE
membrane fractions of CBMCs in both preterm and term infants. The proportions of ARA, DHA and
other LCPUFA were significantly lower in PE and PC of preterm infants compared with those in term
infants. The dominance of ARA was consistent with the process of biomagnification that preferentially
selects ARA rather than other LCPUFA for transfer to the fetus. Preterm infants also had significantly
lower absolute numbers of CD4+ leukocytes and CD4+ and CD8+ naïve T-cells. At birth, there is
a period of transition from a sterile environment to one of higher infectious risk. The elevated levels
of ARA in CBMCs concomitant with lower levels of other LCPUFA suggest that the acquisition of
ARA is needed in preparation for a responsive immune system after birth. These findings indicate
that in preterm infants a deficiency in the supply of ARA exists which may compromise their immune
system [282].
Infants with mildly abnormal physical movements at 12 weeks of age are reported to have
lower ARA content in erythrocyte membranes [283]. This abnormality occurred with maternal
supplementation of DHA alone but was not seen when DHA was combined with ARA during
pregnancy and lactation [283]. Mildly abnormal movements have been also observed during infancy
and linked to increased prevalence of minor neurologic dysfunction and attention deficits at school
age [284]. These findings imply that during early brain development of neonates, a supply of ARA
is critical.
The effects that feeding preterm infants human milk (HM), infant formula without DHA and ARA
(F) or formula with DHA (0.35%) and ARA (0.49%) have on isolated peripheral blood lymphocytes
and lipid composition was evaluated by Field et al. [285]. Adding DHA and ARA to a preterm infant
formula resulted in lymphocyte and cytokine production, phospholipid composition, and antigen
maturity similar to those observed in infants fed human milk. These findings suggest that the addition
of both DHA and ARA may improve the ability of the infant to respond to immune challenges in
a manner similar to breastfed infants [285].
Several epidemiological studies have shown that individuals with learning disorders including
attention deficit hyperactivity disorder (ADHD), dyslexia, and autism have signs of EFA deficiency or
have lower than normal blood levels of DHA and ARA [286–289]. A meta-analysis of pooled data from
RBC and plasma/serum samples indicated that ARA and DHA concentrations were significantly lower
than normal in individuals with learning/developmental disorders [290]. In absolute amounts, the
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level of ARA was as severely depressed as DHA within RBC (both ~0.58 mg/100 mg of fatty acid below
normal) but much lower than DHA within plasma/serum (´0.71 vs. ´0.34). The reason for lower
than normal blood levels of ARA in children with learning disorders is unknown but could be related
to a low dietary intake of ARA relative to metabolic requirements or that ARA is not synthesized
efficiently from precursor fatty acids, or not delivered or properly incorporated into the brain [290].
The effects of subnormal ARA on brain function seems to be independent of those associated with
n-3 deficiency. In Japan where intakes of n-3 fatty acids are relatively high, the incidence of dyslexia
in children is similar to that observed in Westernized countries (~6%) [291]. Therefore, although the
Japanese population consumes sufficient amounts of n-3 fatty acids, there still may be insufficient
intake of ARA to meet the needs for normal brain function during childhood [290]. The important
role of ARA in normal growth and development requires as much research emphasis as DHA has
received. ARA should be the focus of preclinical and clinical research for a detailed assessment of
dietary requirements.
13. The Regulatory Requirements for ARA and DHA in Infant Formulas
A joint International Expert Consultation of the Food and Agricultural Organization of the United
Nations (FAO) and the WHO was assembled in 1976 to review the literature on “The Role of Dietary
Fats and Oils in Human Nutrition” [292]. The section dealing with infant growth and development
indicated that the ideal recommendation for infant formulas would be to match the essential fatty acids
found in human milk with respect to LCPUFA content [292]. The FAO further stated that LCPUFA were
particularly important during fetal and infant growth when there is a high demand for the synthesis of
cell structured lipid [292]. FAO issued a follow-up report in 1994 which provided additional supportive
recommendations for adding both ARA and DHA to infant formulas. The FAO stated that “the n-6
and n-3 fatty acids have critical roles in the membrane structure and as precursors of eicosanoids,
which are potent and highly reactive compounds. Various eicosanoids have widely divergent, and
often opposing effects on, for example, smooth muscle cells, platelet aggregation, vascular parameters
(permeability, contractility), and on the inflammatory processes and the immune system. Since they
compete for the same enzymes and have different biological roles, the balance between the n-6 and the
n-3 fatty acids in the diet can be of considerable importance” [293]. In a follow-up report in 2008–2010,
the FAO/WHO Expert Consultancy on Fats and Fatty Acids further concluded that “There can be little
doubt about the essentiality of DHA and ARA for the brain” [294].
A global standard for infant formula was established by the Codex Alimentarius Commission in
1981, and revised over the years [295]. The latest revision was issued in 2007 and the latest amendment
was added in 2015 [296]. The standard includes details on essential composition of nutrients and a list
of food additives that are allowed to be added. Quality control measures such as labeling, packaging,
contaminants and hygiene are also specified. In the United States, standards for infant formula are the
responsibility of the U.S. Food and Drug Administration (FDA). The U.S. Code of Federal Regulations
Title 21, Part 106 specifies infant formula quality control procedures and Part 107 lists the nutrient
requirements and other rules concerning labeling for infant formulas. Not surprisingly, the quality
and safety standards for infant formulas are extremely high, exceeding most requirements for other
food products [297].
In the European Union (EU), the legislation on infant formula and follow-on formulas was
adopted in 2006 [298] and at the time of this writing is being revised. Before revising the legislation
the European Commission requested the European Food Safety Authority (EFSA) Panel on Dietetic
Products, Nutrition and Allergies to provide their scientific advice on the essential nutrient composition
of infant and follow-on formulas [70,71]. In the first report of 2013, dedicated to nutrient requirements
and dietary intakes of infants and young children in the EU, the EFSA Panel reviewed a variety of
nutrients, including the levels of DHA and ARA. In the 2013 EFSA report, adequate intakes were
defined as 100 mg/day of DHA and 140 mg/day of ARA from birth to six months of age. From 6
to 24 months of age, 100 mg/day of DHA were considered adequate. These recommendations were
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also supported by a global expert panel, based on a systematic review of the available scientific
literature [299]. However, in the subsequent report of 2014, dedicated to essential composition of
infant and follow-on formulae, the EFSA Panel advised that infant and follow-on formulas should
contain relatively higher amounts of DHA (20–50 mg/100 kcal). Mandatory addition of ARA was
not supported in this EFSA report. Still, the Panel noted that feeding an infant formula containing
DHA alone resulted in lower concentration of ARA in erythrocytes compared with a control formula
without DHA.
At an assumed mean fat content of 5.2 g 100 kcal in a typical infant formula, this means that
the recommendation of higher levels of DHA would result in a DHA content of 0.38% to 0.96% of
fatty acids, higher than the 0.2% to 0.3% of DHA currently found in most infant formulas available in
the marketplace [2]. Notably, PUFA-supplemented commercially available infant formulas contain
preformed ARA at levels equal to or higher than the DHA content. The ESFA Panel’s advice of
providing up to 1% DHA and no ARA is a unique approach and directly opposite to a consensus
reached by international expert groups who have recommended that infant formulas for term infants
should contain ARA at levels that range from 0.4% to 0.7% fatty acids (at a 1:1–2:1 ratio to DHA) based
on the median worldwide range of ARA and DHA concentrations in breast milk [6–9].
14. Discussion
ARA is the principle LCPUFA in the inner cell membrane lipid of muscle, heart, vascular
endothelium, adrenals, kidneys, liver, the placenta, and in almost all other organs [300]. ARA is
essential for cell integrity. The cell membrane separates the interior structures of cells from the outside
environment. It also controls the movement of substances in and out of the cell [300]. These membranes
contain signalers, receptors, ion channels, antioxidant defense enzymes, and rafts. Changing any
aspect of the composition of the cell membrane may alter its function [300]).
ARA has very different biological functions than DHA [300]. While DHA controls signaling
membranes in the photoreceptor, brain and nervous system, ARA is indispensable in the vasculature
and in specific aspects of immunity. ARA is important for brain growth during gestation and early
infancy where it plays a critical role in cell division and signaling [11]. A potentially important aspect
of ARA metabolism is its function as a precursor for leukotrienes, prostaglandins, and thromboxanes,
collectively known as eicosanoids. Eicosanoids have numerous critical and specific functions occurring
in almost every tissue of the body. Eicosanoids function to modulate the release of somatostatin, the
principal hormone that stimulates cell proliferation and growth. Eicosanoids also have important roles
in immunity and inflammation.
This review focused on the essentiality of ARA for infant growth and development. Animal
studies demonstrated the importance of ARA for growth and maturation of neurons and myelin and
the resolution of inflammation in models of NEC, influenza and EFA deficiency. These studies also
provided compelling evidence that both preformed DHA and ARA are required for optimal cognitive
and neurological development. The ratio of ARA and DHA added as supplements really matters.
Brain tissue analysis of neonatal baboons fed formula with a high level of 0.96% DHA significantly
reduced ARA levels in two regions of the brain indicating the importance of a proper balance of DHA
and ARA [24].
For over 10 years, both DHA and ARA have been added to infant formulas worldwide in
an attempt to match the nutrient supply and functional benefits achieved with human milk. The
combination of ARA and DHA in infant formulas has been shown to be safe in many millions of
infants globally. The DHA concentration in human milk is lower and more variable than for ARA and
the level of ARA in human milk is more stable [5]. The relatively stability of the ARA level in human
milk is biologically important because it provides preformed ARA consistently at a time when brain
growth and development is most critical [300]. Although DHA is more variable than ARA it is always
present in human milk and the balance between ARA and DHA can be as much as 2 to 1.
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The biosynthetic capability for providing ARA and DHA for brain growth is low and preformed
ARA and DHA are preferentially incorporated into the brain during gestation and early infancy [2,46].
Infant formulas devoid of ARA results in a dramatic decrease of up to 40% of ARA in plasma
shortly after birth [223,230,238,239,300,301], especially in preterm infants who do not receive the third
trimester’s maternal supply of ARA and DHA. The finding that there is a decrease in ARA shortly after
birth shows that biosynthetic capability is insufficient to meet the infant’s demand [300]. The process
of biomagnification and its resulting fatty acid profile further highlights the importance of ARA in
infant growth [45]. In several clinical studies, the provision of high amounts of DHA/EPA without
a concomitant supply of ARA has been associated with adverse effects on growth in premature
infants [240–243].
EFSA [71] recently concluded that “there is no necessity to add ARA to infant formula even in
the presence of DHA”. This recommendation needs further explanation. One of the possible reasons
for this recommendation is that it is generally believed that LA is converted into ARA in sufficient
quantities, even though EFSA noted that feeding an infant formula containing DHA alone resulted in
lower concentration of ARA in erythrocytes compared with a control formula without DHA. From
the limited dietary intake data presented here for non-breastfed infants and young children (Table 1)
living in developing and developed countries there is evidence that intakes of ARA from dietary
sources are very low, much lower than the average amount of ARA available in human milk or infant
formulas containing ARA and DHA. The composition of infant formulas and follow-on formulas
should therefore not only be based on human milk composition but also on food/nutrient intake data
to address the assumption that complementary foods fill nutrient gaps.
The EFSA Panel’s advice of providing higher amounts of DHA (20–50 mg/100 kcal, 0.38% to
0.96% of fatty acids) without a concomitant supply of ARA is also questionable. As discussed here,
DHA suppresses ARA concentration in membranes and its function. As a result, an infant formula
with DHA and no ARA may result in a potential higher risk of morbidity due to the suppression of
favorable eicosanoids that play a key role in cell trafficking, communication and vaso-regulation [45].
EFSA did not take into account the original FAO/WHO publications as well as the earlier
2008–2010 publication which strongly concluded “There can be little doubt about the essentiality of
DHA and ARA for the brain” [294]. When infants are exclusively breastfed during the first 6 months
of life, “there is evidence of a requirement for preformed ARA and DHA after 6 months of life” [294].
According to the 2010 FAO/WHO statement, DHA and ARA should be included in infant formula
with DHA (from 0.2% to 0.5% of total fatty acids) and added ARA should be at least equal to the
amount of DHA [294].
The clinical trials considered by EFSA were not designed to consider the specific physiological
outcomes related to ARA. Most studies included both ARA and DHA. There were no clinical trials that
evaluated the effects of ARA in the absence of DHA. The benefits of ARA + DHA supplementation
cannot be ascribed to DHA alone but logically must be ascribed to the variables used in most of
these studies, the combination of the two. The combination of ARA and DHA has shown benefits for
cognitive development, visual function, and blood pressure well beyond the period of supplementation
and into early childhood [249,302].
EFSA’s lack of support of ARA in DHA-containing formulas relied almost exclusively on the
meta-analysis of infant growth conducted by Makrides et al. [303]. However, the meta-analysis of
Makrides et al. [303] was not comprehensive. The majority of subjects (n = 1050) included in the
meta-analysis participated in 8 clinical trials using formula containing both DHA and ARA. Only 341
subjects in the 8 trials were provided infant formula with DHA/EPA without ARA. At 12 months of
age, only 99 subjects were supplemented with DHA in the absence of ARA. Additionally, the analysis
excluded studies that included preterm infants who are most vulnerable to growth faltering due to
nutrition, and excluded studies in which DHA plus ARA supplementation was less than 3 months
during which growth velocity is particularly sensitive to nutritional inadequacy. The reason for
excluding these studies was not reported.
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In the meta-analysis, Makrides et al. [303] noted that the results were inconclusive, i.e., LCPUFA
supplementation had no detrimental effect on growth. The importance of ARA as a structural and
metabolically active lipid, was not addressed. Better visual and mental performance was attributed to
the contribution of DHA. However, in one of the studies considered, DHA plus ARA improved mental
function [265] compared with an unsupplemented control. In fact, in one study, DHA alone did not
perform better than did the unsupplemented controls [72].
Clinical evidence to support the safe removal of ARA from infant formula and follow-on formula
containing DHA is lacking. The human and nonhuman primate studies described herein question
the EFSA recommendation to provide infant formula from birth with up to 1% of DHA without
a proportional amount of ARA [2]. Any major change in infant formula composition should be
subjected to a full preclinical and clinical evaluation of safety and nutritional adequacy before its
introduction into the marketplace [2]. Without such an assessment, and in light of the universal
presence of ARA in human milk and the numerous essential ARA functions for cell structure and
function, the most judicious approach is to include ARA in DHA-containing infant formulas to promote
optimal infant growth and development.
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